FEBRUARY 2016
TURNING INNOVATION INTO BUSINESS
LUXEMBOURG BIOHEALTH CAPABILITIES
CONTACT Dr Thomas Dentzer Luxembourg BioHealth Cluster Manager thomas.dentzer@luxinnovation.lu Tel: +352 43 62 63 875
More information on the Luxembourg Biohealth Cluster:
www.biohealthcluster.lu Follow us on Twitter (@Luxbiohealth) and LinkedIn
2
LUXEMBOURG BIOHEALTH CAPABILITIES
EDITORIAL by Jean-Paul Scheuren, President, Luxembourg BioHealth Cluster Luxembourg is home to a young, dynamic biomedical sector, which specialises in fields such as personalised medicine, diagnostics, bioinformatics and eHealth. The sector is of strategic importance for Luxembourg’s economy, and its development is backed by solid governmental support. The Luxembourg BioHealth Cluster was established in 2008 in order to bring together the actors in the biomedical field and to enhance the Grand Duchy’s reputation as a recognised and attractive environment for biomedical research, innovation and business. It is experiencing strong growth and currently includes private companies, public research organisations and specialised service providers as well as strategic partners such as the Ministry of the Economy, the Ministry of Higher Education and Research, the Ministry of Health and the National Research Fund. Health sciences and technologies is a highly competitive field, and collaboration between different actors with complementary competences is essential for business and research development. This catalogue showcases the skills, activities and offers of our members, and is a useful guide to anyone interested in establishing R&D collaborations and business relationships in the biomedical field. I thus invite you to discover the capabilities of our members and welcome potential partners to contact the Cluster’s management team. A key role of the BioHealth Cluster is to assist players interested in establishing relationships with the biomedical sector in Luxembourg, or even in locating activities here. We would be delighted to provide you with support, information and further contacts.
LUXEMBOURG BIOHEALTH CAPABILITIES
3
LUXEMBOURG BIOHEALTH CLUSTER The Luxembourg BioHealth Cluster aims to strengthen and capitalise on the national strategy developed by Luxembourg’s government to achieve scientific excellence in molecular diagnostics, the cornerstone of personalised medicine. Its members are R&D companies, public research organisations, laboratories, hospitals and other actors (patients associations, service and capital providers, etc.) whose activities are related to health sciences and technologies. With a principal focus on molecular diagnostics, the Cluster’s umbrella also covers other research and business fields that are key elements in an integrated patientbased personalised medicine approach, such as new therapeutics, bioinformatics and eHealth. Supporting this dynamic and steadily growing biocommunity is the main objective. Therefore, the Cluster provides its members with a portfolio of added-value activities and services to support them in their daily R&D, innovation and business challenges and to increase their national and international visibility and attractiveness.
4
LUXEMBOURG BIOHEALTH CAPABILITIES
THE LUXEMBOURG BIOHEALTH CLUSTER OFFERS THE FOLLOWING SERVICES:
Community management
Global trends
Cooperations
• Information exchange platforms
• Market studies
• Tailored information/opportunities
• Market/business intelligence
• Initiation & support of cooperation projects
• Networking (events, visits, etc.)
• Trend & technology scouting
Sector development
Internationalisation
• Attract companies
• Access to international events
• Contribute to a competitive and favourable environment
• Support to international cooperations
• Foster synergies
• International partnerships
• Partner matchmaking • Project management
Marketing & PR • Information and marketing material • Development of a national identity • Trade fairs & company visits
CLUSTER MANAGEMENT TEAM The Luxembourg BioHealth Cluster activities and support services are managed by Luxinnovation, the National Agency for Innovation and Research. A dedicated Cluster management team is in charge of the daily operational tasks dealing with the implementation of the Cluster strategy and the Cluster action plan.
ARE YOU INTERESTED IN LUXEMBOURG? The Cluster provides foreign companies interested in locating activities in the Grand Duchy with information about the Luxembourg biomedical sector. We can advise you on available support measures, assist you in identifying suitable premises and put you in touch with relevant collaboration partners to set up your activities in Luxembourg. More information on the Luxembourg Biohealth Cluster:
www.biohealthcluster.lu
LUXEMBOURG BIOHEALTH CAPABILITIES
5
SUMMARY P R I VAT E S E C T O R
ACTIMAGE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08 Advanced Biological Laboratories (ABL) / TherapyEdge INC. . . . . . 10 APL – Association pharmaceutique luxembourgeoise. . . . . . . . . . . 12 ATERA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 AxoGlia Therapeutics S.A... . . . . . . . . . . . . . . . . . . . . . . . . . . 16 B Medical Systems S.à r.l... . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Bookmydoc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Cellon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Complix. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 DISTRIBIO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Doctena S.A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 EBRC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Eurofins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 Fast Track Diagnostics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 Flen Pharma S.A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Healthcast.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Hôpitaux Robert Schuman. . . . . . . . . . . . . . . . . . . . . . . . . . . 40 House of Biohealth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 IEE S.A... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 ImNate S.à r.l.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 ITTM (IT for Translational Medicine) S.A.. . . . . . . . . . . . . . . . . . 48 Ketterthill. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 Laboratoires Réunis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Montrium S.A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 Neo Medical Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 Simeda.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58 SISTO Armaturen S.A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 T&E Gefahrgutlogistik AG. . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 WaferGen Bio-systems Europe S.à r.l.. . . . . . . . . . . . . . . . . . . . 64
6
LUXEMBOURG BIOHEALTH CAPABILITIES
IBBL (Integrated BioBank of Luxembourg). . . . . . . . . . . . . . . . . 66
PUBLIC RESEARCH
Luxembourg Centre for Systems Biomedicine (LCSB). . . . . . . . . . 68 Luxembourg Institute of Health. . . . . . . . . . . . . . . . . . . . . . . . 70 Luxembourg Institute of Science and Technology — ITIS. . . . . . . . 72 Luxembourg Institute of Science and Technology — MRT. . . . . . . 74 University of Luxembourg: Life Sciences Research Unit.. . . . . . . . 76
LUXEMBOURG BIOHEALTH CAPABILITIES
7
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Christophe Megel CREATION DATE 1995
CORE BUSINESS Since 1995, ACTIMAGE has been a digital intelligence agency guided by excellence. ACTIMAGE capitalises on twenty years of success in innovation, publishing, development and consulting in information and communication technologies (ICT). The company offers a comprehensive global response to its customers in the following seven areas:
EMPLOYEES 100-249
• digital strategy: consulting services, management assistance, audits;
TURNOVER 2014 €14,000,000
• web and mobile applications content management, graphic design, e-ergonomics;
TRADING AREA Europe
• cloud services: secure telecommunications, networks, hosting;
R&D INTERNAL INVESTMENTS 2014 20% of turnover
• intelligent objects: connected objects, embedded systems, applications;
CERTIFICATIONS, QUALIFICATIONS, Microsoft Gold Partner (Mobility, Portals and Collaborations)
• Software as a Service: highly accessible client tailored solutions;
• data intelligence: data modelling, learning algorithms, optimised IS; • innovation and research: e-health, quantified self, smart-homes.
PRODUCTS & SERVICES As an ICT provider dealing with research and innovation, ACTIMAGE has developed a range of products based on its R&D activities:
INTERNATIONAL LOCATIONS Europe
• actiHome, “Improve safety and wellness at home”, is a service platform at home for the elderly and people with reduced mobility. It addresses three main axes: security, services provision and adaptability. It provides an innovative way to stay at home, receive the necessary medical support and keep contact with family, friends and caregivers. Thanks to new technologies and predictive algorithms, the system is fully adjustable to user needs and behaviour offering them the maximal comfort;
ADDRESS 224 rue de Beggen L-1220 Luxembourg
• Actelin, “Your diabetes companion”, is a smartphone application for diabetic patients. The application is based on functional insulin therapy and delivers advice following its expert system. Predictive algorithms are based on personal history and personal carbohydrates consumption and physical exercise. To make it possible, a large data base of nutriments and typical physical activities is included in the application;
CONTACT Natalia Cassagnes Tel: +352 27 62 15 15 48 innovation@actimage.com WEBSITE www.actimage.com
• Actinote, “Another way of writing”, is a digital pen to scan your handwritten information and send it from anywhere directly into your information system; • ActiBOX, “More than a CMS“, is one of the first management tools, web content 2.0 OpenSource Technologies Ergonomic administration interface; • ActiNet, “For a good organisation“, is a collaborative system of management and internal monitoring.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Since 2001, ACTIMAGE has been actively engaged in innovative activities through a number of European research, development and innovation projects (FP7, AAL, ITEA). The company has been active on topics such as eHealth and SmartHome in cooperation with a number of major European companies and universities. Some examples of its success stories include Guarantee (ITEA 2), Care@Home (AAL) and M3W (AAL). M3W is about monitoring and maintaining the mental wellness of the
8
LUXEMBOURG BIOHEALTH CAPABILITIES
ACTIMAGE
elderly via a platform of serious games. The goal of Guarantee and Care@home is to improve the home safety allowing elderly to live in a secure environment. It also provides some services in order to improve their wellbeing. Currently, ACTIMAGE is involved in SALIG++ (AAL) and DemWatch (ITEA3) projects that pursue the same objectives by exploring new innovative technologies arriving on the market. For exemple, for SALIG++ it has a partnership with the innovative connected pillbox and implements recent WebRTC technology allowing video communication via browser. In these projects, ACTIMAGE is in charge of the intelligent system for sensor management and notification, the elaboration of predictive algorithms, the definition of the architecture of the solution, mobile development, smartTV development, serious games platform development and data hosting. ACTIMAGE intervened in the conception of a European platform for a drug traceability system (European Directorate of Quality of Medecines). ACTIMAGE also works for G.I.E.S (Groupement Informatique de l’Economie Sociale) that was created to address the needs for IT management of several important person services associations. The company is in charge of the centralisation of the G.I.E.S IT infrastructure, including resources management, industrialisation of production methodologies, cost optimisation and compliance with legal requirements about sensitive data.
TECHNICAL / TECHNOLOGICAL CAPABILITIES ACTIMAGE’s innovative staff is made up of PhDs in ICT and the medical area, R&D engineers, technical experts in ICT, ergonomists and designers. ACTIMAGE has expertise in: • software development ( Java, J2EE, C#, .NET, Python, etc.); • mobile and smartTV development (iOS, Android, Windows Mobile, Blackberry, etc.); • web and ergonomy (PHP, HTML5, Drupal, etc.); and
MAIN CUSTOMERS/COLLABORATIONS
• cloud computing and big data.
Health — medicinal — social: Deutsches Rotes Kreuz (Ravensburg), C-PAGE (Health Information System, Dijon), Charity Hospital (Berlin), Fraunhofer Institut (Research Organisation, Berlin), Karlsruher Institut für Technologie (Karlsruhe), Groupement Informatique de l’Economie Sociale (Colmar), Agence de la biomédecine (Saint-Denis La Plaine), Université de Médecine Paris 7 Diderot (Paris), CERBA Laboratory (Saint-Ouen), SCHILLER MEDICAL(Wissembourg), Medissimo (Paris), Office d’Hygiene Sociale “OHS” (Lorraine, France).
TECHNICAL MEANS / EQUIPMENT ACTIMAGE has its hosting platform and a number of strong references from governmental institutions for IT migration and exploitation. The company offers a very secure platform with high availability. Its teams use the ITIL methodology according to the latest technical standards, a guarantee of quality for this type of services. For some clients, it dedicates a team to take care of their infrastructure. ACTIMAGE also has a goal to provide hosting services for health data that particularly sensitive to the security questions. As a Microsoft golden partner, ACTIMAGE has privileged access to Microsoft tools and new technologies. Thus, its clients are offered the latest technological advances and it supports them throughout the change and adjustment phase.
Institutions: Caisse Nationale de Santé (Luxembourg), Luxembourg Ministry of the Economy, Luxembourg Ministry of Foreign Affairs, Syndicat Intercommunal de Gestion Informatique (Luxembourg), European Directorate of Quality of Medecines (Strasbourg), University of Luxembourg, Luxembourg Institute of Science and Technology (Luxembourg), Institut Luxembourgeois de la Normalisation, de l’Accréditation, de la Sécurité et qualité des produits et services (Luxembourg).
LUXEMBOURG BIOHEALTH CAPABILITIES
9
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Chalom B. SAYADA, MD, PhD CREATION DATE 2000 EMPLOYEES 10-49 TRADING AREA International CERTIFICATIONS, QUALIFICATIONS, CE marking for TherapyEdge and In-Vitro Diagnostic use for ViroScore and DeepChek. FinalFive participant of the 2013 Innovation Prize (Universal Biotech) for DeepChek. INTERNATIONAL LOCATIONS Greater Region, Europe, Africa, Oceania
CORE BUSINESS Advanced Biological Laboratories (ABL) S.A., is a medical data technology company founded in 2000 as a spin-off from CRP-Santé (now the Luxembourg Institute of Health (LIH)). ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and OncoChek™, which are used for data and patient management, monitoring and personalised reporting applications. In 2012, some of ABL’s products received CE-marking for IVD use. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput next generation sequencing data.
PRODUCTS & SERVICES ABL develops and implements several products and services around its web-based and local TherapyEdge® Box System to deliver the best therapies for people living with complex, chronic diseases: • TherapyEdge® is an electronic medical record (EMR) system with dedicated HIV content with decision support, monitoring and reporting system with builtin decision support (TherapyEval) and various modules (RapidCapture, DownReferral, Peads, HealthScan, eRegister); • HepatiC is a viral hepatitis C patient registry and database to monitor and screen HCV infected patients; • ViroScore® Suite is an HIV drug resistance interpretation system and sequence storage database with built-in analysis and reporting tools;
ADDRESS 52-54 avenue du X Septembre L-2550 Luxembourg
• SeqHepB is an online decision support system for HBV drug resistance information acquired from Evivar Medical (co-developed with Melbourne Health University, Australia) with the largest HBV drug resistance knowledge database;
CONTACT Dr Chalom Sayada Tel: +352 26 38 89 21 info@ablsa.com
• DeepChek®-HIV is the first CE-IVD marked medical device for next generation sequencing data management (Roche 454, Illumina MiSeq/HiSeq, Ion Torrent PGM, SmartR PacBio, etc.). DeepChek® modules for HBV and HCV are also available for NGS;
WEBSITE www.ablsa.com
• ABL has launched its first bioinformatics pipeline for oncology, OncoChek™, and is working on new virology and bacteriology applications; • ABL has the ability to work on full genome data analysis; • VisibleChek™ is the first-application for data visualization and data mining able to merge clinical, virological and advanced molecular (Sanger/NGS) information.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Since 2000, ABL has leveraged a large experience in virology (HIV and viral hepatitis) for patient management either from clinical, virological and molecular sides. ABL has acquired the assets of TherapyEdge® Inc. for HIV and Evivar Medical Pty for HBV. These assets are patents, software and knowledge databases. ABL continue investing resources in infectious diseases to support its product portfolio.
10
LUXEMBOURG BIOHEALTH CAPABILITIES
Advanced Biological Laboratories TherapyEdge INC
ABL recently inked an agreement with LIH for getting the exclusive commercial rights on COMET technology. ABL is also engaging strong collaborations in the fields of microbiology and human genetics for developing new applications in tuberculosis and oncology. ABL continues its efforts to bring the latest technologies for server virtualisation, web development with strong capacities of data security and data encryption, bioinformatics scripts and methods for fast and reliable data management and analysis of next generation sequencing information.
TECHNICAL / TECHNOLOGICAL CAPABILITIES ABL is able to develop secure network (intranet, internet, VPN) platforms for the electronic management of clinical information between distributed units. ABL’s technology is a ready-to-run solution for all the technical problems that users face. The developed platforms are based on state-of-the-art technologies. ABL offers a service adapted to each clinical setting and can implement electronic case report forms. The company can combine the secure collection of data with real time analysis systems. ABL is also able to develop specifically: • algorithm-based genotype interpretation systems; • tools for the management of sequences; and • advanced genetic analysis tools to integrate complex clinical and virological information.
TECHNICAL MEANS / EQUIPMENT ABL products lie on a proprietary platform server (hardware, virtual or internet-based). End-users access the various pieces of software using web-browser. It could be used by clinicians, pathology laboratories, private insurance companies, diagnostics and pharmaceutical companies. ABL’s platform is fully integrated with patient management systems (PMS or HER), pharmacy information system (PIS), laboratory information system (LIS) using its integration engine with standard data exchange protocols (HL7, XML). It could be integrated to any type of network to implement new electronic case report forms, engage specific data collection on investigating sites, generate printout of case report forms in paper format (PDF), display graphics for patients, automated data extraction, database query, push technologies (alerts, SMS ...).
• AEEH, Spanish Association of Hepatologists for HCV; • Spanish HIV Foundation (Badalona, Barcelona) for HIV & NGS; • South Africa National Health Laboratory Service (NHLS); • European Society for Antiviral Resistance;
MAIN CUSTOMERS / COLLABORATIONS • Luxembourg Institute of Health (LIH); • Latin American Liver Research Awareness and Educational Network (LALREAN) for HCV;
• TINN2 (FP7 EU Project); • Roche Diagnostics International and other major Pharma and Dx companies; • Tute Genomics (Oncology, human genetics).
LUXEMBOURG BIOHEALTH CAPABILITIES
11
P R I VAT E S E C TO R PUBLIC RESEARCH
SECRETARY GENERAL Hendrik Kühne CREATION DATE 2011 EMPLOYEES 0-9 TURNOVER 2012 €170,000 TRADING AREA Luxembourg INTERNATIONAL LOCATIONS Europe
CORE BUSINESS The Association pharmaceutique luxembourgeoise (APL) is the representative body for the innovative pharmaceutical industry active in Luxembourg. With 40 members (as of October 2015), APL covers some 76% of the pharmaceutical market in Luxembourg. APL being a young association, the number of members is still growing. APL’s main goal is to establish an open and trustworthy contact with Luxembourg decision-makers and stakeholders in order to promote stability, predictability and a general dialogue in partnership.
PRODUCTS & SERVICES APL wants to promote stability for the Luxembourg pharmaceutical market. This means access for everyone to all available treatments, and this over a longer period of time. The current Luxembourg health system is characterised by high investments in general and good quality for patients regarding the access to new medications. In order to maintain these specific Luxembourg qualities, APL would like to engage with national authorities in open discussions on future challenges for the healthcare system.
ADDRESS 7, rue Alcide de Gasperi L–2981 Luxembourg CONTACT Hendrik Kühne Tel: +352 26 43 23 24 info@apl-pharma.lu WEBSITE www.apl-pharma.lu
12
LUXEMBOURG BIOHEALTH CAPABILITIES
On the other hand and towards its members, APL is promoting Luxembourg as a possible partner for R&D activities, putting forward in particular IBBL, LCSB, Luxembourg Institute of Health (LIH) and other prominent research bodies in Luxembourg. APL would like to see all concerned authorities engaging together in a broad dialogue about the future of possible pharmaceutical investments in Luxembourg, in order to benefit patients (quick access to innovation), the Luxembourg economy (employment and tax revenues), research as a whole in Luxembourg (abovementioned bodies as well as researching practitioners) and the industry (stability and predictability).
APL Association pharmaceutique luxembourgeoise
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Achieving a mid- and long-term previsibility of national health economics.
TECHNICAL / TECHNOLOGICAL CAPABILITIES Pharmaceuticals
MAIN CUSTOMERS / COLLABORATIONS Public healthcare authorities and other stakeholders in public health.
LUXEMBOURG BIOHEALTH CAPABILITIES
13
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Bart De Wever CREATION DATE 2015 EMPLOYEES 0-9 TRADING AREA International
CORE BUSINESS ATERA S.A. is a tissue engineering company focusing on research and development, validation, manufacturing and commercialisation of advanced human tissue models for medical research and industrial safety and efficacy testing, gradually replacing animal experimentation. ATERA stands for Advanced Tissue Engineering for Research Applications.
PRODUCTS & SERVICES ATERA produces a variety of human tissue models including: • skin models: Reconstructed human epidermis; reconstructed human pigmented epidermis; “psoriasis-like” reconstructed human epidermis; • mucosal models: reconstructed human gingival epithelium; reconstructed human oral epithelium; reconstructed human vaginal epithelium; and
ADDRESS 29, rue Henri Koch House of BioHealth L-4354 Esch-sur-Alzette CONTACT Alexandra Sandu Tel: +352 661 73 21 01 a.sandu@ateralabs.com WEBSITE www.ateralabs.com
14
LUXEMBOURG BIOHEALTH CAPABILITIES
• eye models: reconstructed human conjunctival epithelium. In addition, a variery of CRO services including toxicity tests and efficacy tests are offered.
ATERA S.A.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS ATERA’s R&D activities focus on the development of advanced human tissue models. The company is engaged in multiple international collaborative projects with health institutes in Luxembourg and elsewhere. In particular the development of human corneal models, intestinal, and blood brain barrier, as well as infectious disease models are the company targets.
TECHNICAL / TECHNOLOGICAL CAPABILITIES ATERA is building a 200 m2 lab space at the House of BioHealth in EschBelval, intended to host both R&D and production facilties. In line with the company’s global vision, the creation of additional laboratories, especially in the US, is envisioned in the near future.
LUXEMBOURG BIOHEALTH CAPABILITIES
15
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Jean-Paul Scheuren CREATION DATE 2006 EMPLOYEES 0-9 TRADING AREA Europe R&D INTERNAL INVESTMENTS 2012 €200,000
ADDRESS 162a avenue de la Faiencerie L-1511 Luxembourg CONTACT Dr Djalil Coowar Tel: +352 46 66 44 64 45 dcoowar@axoglia.com WEBSITE www.axoglia.com
CORE BUSINESS AxoGlia Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative drugs for the treatment of neurodegenerative and inflammatory diseases with unsatisfied medical needs (Multiple Sclerosis (MS), Parkinson’s Disease (PD), etc.). The company is a pioneer in the development of small chemical entities having dual anti-neurodegenerative and anti-inflammatory capacities. These molecules act on two levels: the regeneration of nervous cells by influencing the cell fate of cellular precursors and having anti-inflammatory/neuroprotective properties.
PRODUCTS & SERVICES AxoGlia’s pipeline consists of drug candidates aiming to stimulate and promote the patient’s own resident neural stem/progenitor cells to differentiate and become functional for endogenous repair. AxoGlia responds to an unmet medical need as no medication currently marketed or close to marketing approval has demonstrated a curative effect for either pathology. Its lead compounds for MS have anti-inflammatory activities and the capacity to promote the differentiation of oligodendrocyte precursor cells for enhancing remyelination processes and axonal protection. Company highlights: • cell-based functional analysis to identify the right lead compounds; • focus on brain repair by CNS regeneration and neuroprotection for a curative approach; and • assays combine neurogenesis enhancement, neural precursor cell differentiation and neuroprotection.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS AxoGlia has identified Glycogen Synthase Kinase-3 (GSK-3) inhibitors which are able to modulate the activation of microglia and polarise them towards a neuroprotective profile with the secretion of anti-inflammatory and anti-oxidant molecules. These inhibitors have demonstrated these anti-inflammatory characteristics through the activation of the Nrf2 pathway. These findings pave the way for rapidly developing a preclinical drug candidate for MS or PD. This opens a real perspective for the development of AxoGlia’s pipeline of drug candidates. A major project financed by the Michael J Fox Foundation is to determine if disrupting the inflammatory CD40-CD40L pathway is of therapeutic benefit in mouse models of PD. This could open a new avenue for therapeutic intervention in PD. Antibodies neutralising CD40 or CD40L exist and are currently being clinically tested to treat autoimmune diseases and organ rejection after transplantation. They could be tested in PD models in a follow-up to the study.
16
LUXEMBOURG BIOHEALTH CAPABILITIES
AxoGlia Therapeutics S.A.
TECHNICAL / TECHNOLOGICAL CAPABILITIES AxoGlia’s drug discovery platform consists of functional screens for assessing cell differentiation and immunomodulatory capacities. At first, compounds are evaluated on neural stem cells (NSCs) and macrophages for these activities and further in vitro tests on primary cells are realised to confirm the CNS regenerative and anti-inflammatory potential of hit candidates. Depending on early PK studies of hit candidates, pharmacological validation on animal models is then realised to assess the clinical outcome for MS and PD. AxoGlia’s mission is to identify the most promising candidates for a regenerative approach to CNS diseases.
MAIN CUSTOMERS / COLLABORATIONS AxoGlia works with scientific and clinical key opinion leaders in neurodegenerative disorders. Collaboration is ongoing with the Luxembourg Centre for Systems Biomedicine for systems biology approaches to understand the molecular mechanisms leading to PD and to identify new innovative therapeutic targets. A scientific partnership has also been developed with a Spanish academic group to develop new innovative drug candidates focusing on neurogenesis and neuroprotection.
LUXEMBOURG BIOHEALTH CAPABILITIES
17
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Luc Provost CREATION DATE 2014 EMPLOYEES 100-249 TURNOVER 2012 €32,000,000 TRADING AREA International CERTIFICATIONS, QUALIFICATIONS, ISO 9001, ISO 14001 INTERNATIONAL LOCATIONS Europe, Africa, North America, South America, Asia, Oceania
ADDRESS 17, op der Hei L-9809 Hosingen CONTACT Silvia Pereira Tel: +352 92 07 31 28 1 silvia.pereira@bmedicalsystems. com WEBSITE www.bmedicalsystems.com
18
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS B Medical Systems S.à r.l. is a pioneer in the medical industry. The company was founded in 1979 when the World Health Organization approached Electrolux in Vianden, Luxembourg, to provide a solution to their problems in safely storing and transporting vaccines around the world. Subsequently, the Electrolux refrigeration division became the Dometic Group. In March 2015, Navis Capital Partners and the management team acquired the medical division from the Dometic Group under the new name B Medical Systems S.à r.l.. The name change reflects the deep conviction of the team and shareholders, to continuously deploy dedicated solutions in its customers in the healthcare field. B Medical Systems specialises in research, development and the manufacture of professional refrigerators, freezers, storage and solutions for safe transport and management of blood and vaccines. With its worldwide network of distributors, its own research and development capability and flexible manufacturing facilities, it will continually strive for excellence in product development, manufacturing and customer service across all of its product lines. The company is committed to exploring new technologies, increasing the variety of its products and seeking new fields of business. B Medical Systems is a flexible, innovative and customer-oriented company, which has always been recognised for the excellence and performance of its products. It has always based its reputation on one rule: “never compromising on standards” to deliver the best performance these programmes deserve, for humanity. Over the past few years, the company has been supported extensively and passionately by its regional consultants and country partners who dedicate themselves to its cause and have gained credibility in their own right with the regional agencies and country authorities.
B Medical Systems S.Ă r.l.
PRODUCTS & SERVICES B Medical Systems currently exports reliable refrigerators and freezers as well as transport boxes for vaccines, blood and blood products, laboratory and pharmaceutical issues in the whole world. The products cover the spectrum of the specific and exacting needs of the market: hospitals, laboratories, pharmacies, blood banks, research centres, biotechnology and universities.
LUXEMBOURG BIOHEALTH CAPABILITIES
19
P R I VAT E S E C TO R PUBLIC RESEARCH
CORE BUSINESS
CEO Theresa Baumg채rtner
Online appointments for healthcare professionals.
CREATION DATE 2013
PRODUCTS & SERVICES
EMPLOYEES 0-9 TRADING AREA Greater Region
ADDRESS 243, avenue Gaston Diderich L-1420 Luxembourg CONTACT Theresa Baumg채rtner Tel: +352 621 66 40 53 info@innovatum.lu WEBSITE www.bookmydoc.lu
20
LUXEMBOURG BIOHEALTH CAPABILITIES
Bookmydoc.lu and Bookmykine.lu are two platforms in Luxembourg to help patients find a doctor or healthcare professional and easily book an early appointment online with instant booking confirmation. Several healthcare professionals use the appointment solutions to let their patients book appoitments online with no need anymore to use the phone. The platforms work 7/7 24/24. The Bookmydoc platform has received over 600,000 visits by users since the launch in 2013.
Bookmydoc by Innovatum
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Help patients to easily have healthcare appointments.
TECHNICAL / TECHNOLOGICAL CAPABILITIES Online 24/24 health care search and booking system.
LUXEMBOURG BIOHEALTH CAPABILITIES
21
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Richard Fry CREATION DATE 1987 EMPLOYEES 10-49 TRADING AREA International CERTIFICATIONS, QUALIFICATIONS, ISO 9001 - 2008 INTERNATIONAL LOCATIONS Europe
CORE BUSINESS Cellon provides products and services to the vaccine production and bioprocessing industries, including the manufacture of: • PharmaTainers — sterile, single use bottles and carboys for the storage and transport of bulk vaccines, biopharmaceuticals, culture media and other biotech materials that are certified to USP 788, EP 2.9.19 and JP 14th ed. Part 1 sect 24 criteria for particulate in injectable liquids; • Octopus Assemblies — custom assemblies developed to meet specific customer requirements for closed liquid transfer solutions.
PRODUCTS & SERVICES Cellon’s areas of expertise include mammalian cell culture processes, 3D tissue culture, tissue engineering, storage and transport of sterile liquids and vacuum measurement.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS
ADDRESS ZAE Robert Steichen 16 Rue Héierchen L-4940 Bascharage CONTACT Richard Fry Tel: +352 26 33 73 1 cellon@gms.lu WEBSITE www.cellon.lu
Cellon undertakes a wide range of collaborative development projects with customers to develop custom solutions to their specific requirements for asceptic liquid transfer. In addition, Cellon is coordinating the EU Seventh Framework Programme for research and technological development (FP7) project SpeCCC and is participating in the NEXT project supported by the FP7 under Grant Agreement n° HEALTH.2013.1.3-2-602235. The core objective of the SpeCCC project is to develop specialised 3D functional liver cell carrier components for use in homogeneous scalable bioreactor systems, including specialised liver cell lines, specialised cell carriers, a bioartificial liver device (BAL), a multibioreactor platform format for drug testing and biotransformations and a multiwall plate system incorporating specialised carrier components for drug testing and toxicity testing. The NEXT project “Nano Engineering for Cross Tolerance: new approach for bioengineered, vascularised, chimeric islet transplantation in nonimmunosuppressed hosts” aims to develop the next generation of chimeric pancreatic islet for diabetes 1 treatment. NEXT will provide a 360° solution to the pitfalls of current methodology for pancreatic islet transplantation: • nano technologies, to engineer donor cell surfaces in order to derange recognition and suppress their rejection; • advanced tissue engineering methods, to assemble bio synthetic islet, enriched by chimeric microvasculature; and • innovative double immune-suppressive strategy using immunosuppressive nano peptides.
22
LUXEMBOURG BIOHEALTH CAPABILITIES
Cellon
TECHNICAL / TECHNOLOGICAL CAPABILITIES Clean manufacture (particle free) of single use disposables. The Rotary Cell Culture System from Synthecon is a unique bioreactor system. The RCCS creates an environment that enables extremely fragile cell cultures and co-cultures of human and animal cells to grow into complex, sophisticated three-dimensional models in vitro. The cultures mimic the structure and function of their parental tissue. The RollerCell 40 is a roller bottle processing system. It has been designed to automate all stages of roller bottle based cell culture — from cell inoculation, incubation, media change and tryptinisation through to final harvest. The EggMaster III egg cutting and harvesting system provides fast and effective inspection and processing of inoculated, embryonated eggs for the biotechnology industry. The VacTester XK systems have been developed to provide rapid, reliable and non destructive detection and quantification of vacuum within vials of parenteral drugs. Octopus Assemblies are custom designed assemblies for biopharma manufacturers.
TECHNICAL MEANS / EQUIPMENT PharmaTainers are manufactured in a state of the art ISO class 5 (class 100) environment and batch release tested by liquid particle count technology to enable certification to meet USP 788 EP 2.9.19 and JP 14th ed. Part 1 sect 24 criteria for particulate in injectable liquids. Octopus Assemblies is custom-designed for biofunctional manufacturers. Octopus Assemblies are manufactured at an ISO 9001/2000, BS EN ISO 13485:2003, FDA registered facility in a BS ISO 14644-1:1999 ISO Class 7 (Class 10,000) Cleanroom.
MAIN CUSTOMERS/COLLABORATIONS Cellon is an established supplier to many of the largest biopharma, human and animal vaccine manufactures in Europe and worldwide.
LUXEMBOURG BIOHEALTH CAPABILITIES
23
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Mark Vaeck CREATION DATE 2008 (Belgium) 2010 (Luxembourg) EMPLOYEES 10-49 TRADING AREA Europe INTERNATIONAL LOCATIONS Europe
CORE BUSINESS Complix is a biopharmaceutical company focused on the discovery and the development of Alphabodies™, a unique class of therapeutics with the capacity to address a vast number of disease targets that are currently considered “undruggable” by the two main classes of therapeutics: small chemical drugs and therapeutic antibodies. Alphabodies™ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. In particular, the ability of Alphabodies™ to modulate the intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of many important diseases, represents a major medical and commercial opportunity for Complix and its partners. Due to their unique stability and versatility Alphabodies™ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
PRODUCTS & SERVICES ADDRESS 84 Val Fleuri L-1526 Luxembourg CONTACT Sabrina Deroo Tel: +352 26 97 02 13 sabrina.deroo@complix.com WEBSITE www.complix.com
The Alphabody™ drug development engine is based on the vision that an ideal therapeutic protein should contain a set of key properties that are not present, in a combined way, in monoclonal antibodies or in any other currently available therapeutic proteins. By integrating structural properties of certain naturally occurring human proteins with computer-aided design concepts, the scientific founders of Complix have developed a novel protein scaffold that harbors many of the desired characteristics of an optimal therapeutic molecule: the “Alphabody™”. Alphabodies™ are a revolutionary class of protein therapeutics that combine the attractive features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs, such as extreme stability and their capacity to penetrate cells. These unique features enable Alphabodies™ to address a wide range of disease targets, both intracellular and extracellular, that are considered undruggable by current drug formats, namely small chemicals or biologics.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Complix has been developing Cell-Penetrating Alphabodies (CPABs), which have the unique capacity to enter cells effectively and modulate intracellular protein-toprotein interactions (PPIs), which are known to play a key role in the initiation and progression of major diseases such as cancer, autoimmunity, CNS and metabolic diseases.
24
LUXEMBOURG BIOHEALTH CAPABILITIES
Complix
TECHNICAL / TECHNOLOGICAL CAPABILITIES By integrating expert knowledge on structural elements of naturally occurring human proteins with computer-aided rational design concepts, the scientific founders of Complix have created a novel protein scaffold that harbors many of the desired characteristics of an optimal therapeutic molecule: the “Alphabody™”. Applying their proprietary AlphaSelect technology, Complix researchers have already isolated and characterised Alphabodies™ that bind selectively to functional targets involved in the inflammation cascade, in tumour growth regulation and in viral infection. Through the filing of several broad patent applications Complix has established a strong intellectual property position on the Alphabody™ technology. Because the Alphabody™ scaffold structure is totally unrelated to immunoglobulins, Alphabodies™ are independent of antibody based patent claims.
MAIN CUSTOMERS / COLLABORATIONS Complix has established research alliances with VIB, a life sciences research institute in Belgium and the Luxembourg Institute of Health (LIH), a public research organisation for basic, pre-clinical and clinical research in life sciences in Luxembourg.
Structure of an Alphabody
Intracellular presence of cell penetrating Alphabody
LUXEMBOURG BIOHEALTH CAPABILITIES
25
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Bertrand Daniel CREATION DATE 2005 EMPLOYEES 0-9 TURNOVER 2014 €3,000,000 TRADING AREA International
CORE BUSINESS Genomics and proteomics, products and services for researchers, hospitals and diagnostics labs.
PRODUCTS & SERVICES The company has two main activities: • custom services: synthetic genes, peptides, antibodies, SiRNA, oligonucleotides, viral services, protein purification, expression, etc; and • instrumentation: revamping of used lab equipment, DNA sequencers, RT-PCR systems, thermocyclers, DNA synthesizers, peptide synthesizers; maintenance and reagents.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Specialists in DNA sequencers and RT PCR systems.
ADDRESS 6 rue D. Lang L-3505 Dudelange CONTACT Bertrand Daniel Tel: +352 27 62 04 11 info@distribio.com WEBSITE www.distribio.com
26
LUXEMBOURG BIOHEALTH CAPABILITIES
DISTRIBIO Laboratoire de Biotechnologie du Luxembourg S.A.
TECHNICAL / TECHNOLOGICAL CAPABILITIES Specialists in DNA sequencers and RT PCR systems.
TECHNICAL MEANS / EQUIPMENT Workshop and laboratory in Dudelange.
MAIN CUSTOMERS / COLLABORATIONS The company has more than 1,000 customers in its files and around 400 active customers each year.
LUXEMBOURG BIOHEALTH CAPABILITIES
27
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Patrick Kersten CREATION DATE 2013
ADDRESS 35a av JF Kennedy L-1855 Luxembourg CONTACT Patrick Kersten Tel: +352 20 40 41 30 contact@doctena.com WEBSITE www.doctena.lu
28
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS Doctena helps patients book medical appointments online. The Doctena platform shows an aggregated view of doctor agendas. Patients can pick appointments and request a booking confirmation online. Doctena makes the best use of the newest online and mobile technologies that can be implemented in medical practices. Availabilities are easily made public and filled by new patients. Patients get faster access to healthcare. Both parties benefit instantly from the implementation of the Doctena tools.
PRODUCTS & SERVICES Helping patients get access to healthcare is the focus of Doctena. Adding transparency to the medical schedules is a major innovation for both patients, referring doctors and medical teams. Current booking processes mostly rely on telephone operators picking slots whilst many sectors have already switched to online bookings to boost efficiency. Seamless in the existing environment of the Doctena tools is key to being able to answer the increasing demand of patients for online agendas.
Doctena S.A.
TECHNICAL / TECHNOLOGICAL CAPABILITIES Technology has not made practitioners’ appointment system more efficient as multiple types of software are being used and very few of those communicate with each other. Doctena focuses on creating links between those agendas, bringing the content online and making it portable. Being from Luxembourg, Doctena is particularly aware of the language issue and has developed the first platform for medical appointments with focus on multi-lingual environments.
MAIN CUSTOMERS / COLLABORATIONS Numerous doctors, practitioners, medical teams and paramedical teams rely on Doctena for the management of their agenda and booking tool.
LUXEMBOURG BIOHEALTH CAPABILITIES
29
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Yves Reding CREATION DATE 2000 EMPLOYEES 100-249 TURNOVER 2014 €48,000,000 TRADING AREA International CERTIFICATIONS, QUALIFICATIONS, 3 Tier IV Data Centers certified, inclunding 2 Tier IV Constructed Facility, PCI DSS level 1, Eco Data Center Star Audit 5*, ISO 27001, ISO 20000, ISO 9001, ISO 14001, ISO 50001, ESR (Corporate Social Responsibility), Accredited Tier Designers, Risk Managers (ISO 27005), ITIL V3, Prince2, IT Security consultants, Business Continuity & Disaster Recovery Certifications (BCI, DRII, ISO 22301) INTERNATIONAL LOCATIONS Europe
CORE BUSINESS EBRC is a leading service provider in the management of sensitive information. Historically recognised as an expert in the banking sector and financial markets, EBRC today ensures the highest level of security and confidentiality in managing critical information such as personal health data. Using its understanding of healthcare issues as a basis, EBRC has developed a professional and comprehensive range of dedicated services, from best-class data centre services to added-value ICT managed services and ready-to-use cloud scalable platforms. EBRC as a single layered provider offers a complete range of services from advising and consulting facilities to integrated managed services aligned with business needs and requirements (SPOC).
PRODUCTS & SERVICES • Trusted Advisory Services: guidance and advice on the management of ICT risks, consolidation and transformation. Consulting and auditing of infrastructure and operations to prepare new architecture and service delivery till outsourcing; • Trusted Managed Services: end-to-end management of sensitive ICT infrastructures, from architecture design and implementation to daily operations and future developments; • Trusted Cloud Europe: flexible infrastructure management through Infrastructure as a Service (IaaS) and Platform as a Service (PaaS) service models as well as trusted back-up and restore services; • TrustedCloudFactory: an innovative development and test portal built in partnership with InTech which significantly boosts Time-to-Market by reducing the integration phase (“wall of incomprehension”); • Trusted Security Europe: EBRC “Trusted Security Europe” and its “Managed Security Services” (MSS) enable clients to focus on their core business while EBRC takes care of their IT infrastructure and related threats to data and communication. • Trusted Resilience Services: design, implementation and management of business continuity solutions coupled with the management of ICT security based on resilient infrastructures;
ADDRESS 5 rue Eugène Ruppert L-2453 Luxembourg CONTACT Yves Reding Tel: +352 26 06 1 info@ebrc.com WEBSITE www.ebrc.com
30
LUXEMBOURG BIOHEALTH CAPABILITIES
• Trusted Data Centre Services: full data centre services based on redundant Tier IV certified infrastructures for highest security and availability. In the framework of the PFS status, EBRC meets the requirements of the CSSF, and is therefore allowed to operate ICT services for banks, financial institutions and investment fund companies. These qualities and security requirements are considered as best practices within EBRC and are to be met for any client managing sensitive information (biotech & health, ePayment, eCommerce, international institutions, public sector, industry, SMB, gaming, etc.).
EBRC
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS DSP project: A unique project in terms of its originality, size and importance. For the first time, patients become actors in their own medical treatment and care. The data for the DSP (“Dossier Soins Partagé”, i.e. shared medical record) was sent to the eHealth platform in 2014.
TECHNICAL / TECHNOLOGICAL CAPABILITIES EBRC is an expert for the management of sensitive information declined as pure protection and high availability. EBRC provides all existing facilities from data centre to engineered services to consolidate a onestop-shop solution interface. The platform choices are done with high standards and market leaders such as CISCO, VMware, MS or RED HAT.
TECHNICAL MEANS / EQUIPMENT ERBC’s expertise and, in particular, advisory services enable the company to be a leading partner for designing and optimiseing a platform architecture related to business objectives and operation services. With EBRC, clients can find Trusted Cloud Europe solutions to host sensitive information, 3x Tier IV certified data centre to build a strong presence on the Internet network. In order to reinforce the management of sensitive information, EBRC SOC (Security Operations Centre) was formed by experts offering a mutualised service, providing companies with a more reliable and sustainable security. Those has been recognised by eSanté or the FinTech ecosystem, demonstrating the expertise and highly advanced technology of EBRC.
MAIN CUSTOMERS / COLLABORATIONS IBBL, Integrated BioBank of Luxembourg, with a trusted third party role to manage the identification and pseudonomisation process. Major laboratory under NDA with a full cloud transformation solution to optimise their infrastructure. Agence Nationale eSanté with the DSP Project, the NCP of the Epsos programme. EBRC has built a community health cloud to support their activities with a full secured and highly available environment.
LUXEMBOURG BIOHEALTH CAPABILITIES
31
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Gilles Martin CREATION DATE 1987 EMPLOYEES 250< TRADING AREA International INTERNATIONAL LOCATIONS Greater Region, Europe, Africa, North America, South America, Asia, Oceania
ADDRESS Val Fleuri 23 L-1526 Luxembourg CONTACT Dr Gilles Martin Tel: +352 26 18 53 20 info@eurofins.com WEBSITE www.eurofins.com
32
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
PRODUCTS & SERVICES Eurofins offers the most comprehensive range of analytical methods available anywhere in the world through its global network of laboratories. Customers have access both to local laboratories for fast turn-around testing and a strong local relationship, and also to expertise from its vast network of laboratories, provided in particular by the groupâ&#x20AC;&#x2122;s specialist competence centres.
Eurofins
TECHNICAL / TECHNOLOGICAL CAPABILITIES Today the Eurofins Group is a leading provider of analytical services with: • an international network of more than 200 laboratories across 38 countries in Europe, the USA, Asia-Pacific and South America; • 20,000 staff; • a portfolio of over 130,000 reliable analytical methods; and • more than 100 million assays performed each year to establish the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products.
LUXEMBOURG BIOHEALTH CAPABILITIES
33
P R I VAT E S E C TO R PUBLIC RESEARCH
HEAD OF MARKETING AND EXTERNAL RELATIONS Graham Samson CREATION DATE 2014 EMPLOYEES 10-49 TURNOVER 2014 >€6,000,000
CORE BUSINESS Syndromic real-time PCR multiplexing that serves the clinical need. Fast-track diagnostics produces an extensive range of advanced multiplex assays for the detection of viruses, bacteria, fungi and parasites. Standard protocols mean that the assays are easy to introduce to the work-flow, and they are used in routine daily use in over 500 laboratories worldwide. Syndromic grouping of the tests leads to quick, reliable, clinically relevant results to help clinicians minimise uncertainty for patients. The tests are compatible for use on a wide variety of real-time PCR platforms and all the reagents necessary are supplied in kits to suit small, medium and large laboratory needs.
TRADING AREA International
PRODUCTS & SERVICES
R&D INTERNAL INVESTMENTS 2014 >€400,000
Fast-track diagnostics assays are grouped to aid the identification of the underlying cause of most infection syndromes facing the clinician — for example, respiratory, diarrhoea, meningitis, red eye and fever — which means that the clinician does not need to request that a specific pathogen be tested for in a patient sample, which is usually very difficult using clinical criteria alone.
CERTIFICATIONS, QUALIFICATIONS, ISO 13485:2003 since August 2011. Development, production and customer support systems are assessed by TüV Süd every year INTERNATIONAL LOCATIONS Europe, Asia
ADDRESS 38, rue Hiehl, Z.A.C Laangwiss L-6131 Junglinster CONTACT Graham Samson Tel: +352 78 02 90 329 graham.samson@fasttrackdiagnostics.com WEBSITE www.fast-trackdiagnostics.com
34
LUXEMBOURG BIOHEALTH CAPABILITIES
As all the assays are multiplexed, this not only allows the detection of all the pathogens causing a patient’s illness, it is also the most cost-effective way of detecting multiple pathogens simultaneously. By eliminating the need for additional runs and more tubes of reagent, using Fast-track diagnostics assays keeps the cost per patient sample to a minimum. Fast-track diagnostics offers kits packaged to suit small, medium and large laboratories. The 4 patient-per-run size comes in 24 patient tests per kit; the 6 patient-per-run size comes in 48 patient tests per kit; and the 12 patient-per-run size comes in 96 tests per kit. The laboratory work-flow is simplified and more time-efficient as all the assays are performed using identical extraction and pipetting protocols, and use the same thermal cycling profile to allow faster through-put and more effective use of real time PCR platforms.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Fast-track diagnostics has a commitment to research and diagnostic laboratories in the emerging world. Its kits are used by the GABRIEL network as well as for projects funded by the Wellcome Trust and the Bill and Melinda Gates Foundation-funded PERCH project.
Fast Track Diagnostics
TECHNICAL / TECHNOLOGICAL CAPABILITIES Fast-track diagnostics offers more than 50 different real time PCR assays detecting more than 100 pathogens. Its focus is to offer affordable, high quality products for all sizes of diagnostic and research laboratories.
TECHNICAL MEANS / EQUIPMENT Fast-track diagnostic kits detect up to four different pathogens per tube using four different dyes, so only the real-time PCR cyclers that can detect these dyes, the excitation and emission wavelengths, are suitable. A list of the instruments that are fully validated with Fast-track diagnostic kits is given below (when the LightCycler480® is used, to correct crosstalk, Fast-track diagnostics offers a colour compensation kit free of charge). Compatible real-time PCR thermocyclers: • Applied Biosystems® 7500, 7500 Fast and ViiA7 (life technologies™); • Rotor-Gene 3000, 6000 and Q (Qiagen); • CFX96® and DX® with CFX software (Bio-Rad); • LightCycler® 480 (Roche); and • SmartCycler® with Life Science software 2.0d (Cepheid). Recommended automatic, semi-automatic and manual extraction methods to use with Fast-track diagnostic assays are listed on their website.
MAIN CUSTOMERS / COLLABORATIONS Fast-track diagnostic kits are used by more than 500 public and private molecular biology and research laboratories worldwide, by the GABRIEL network and for projects funded by the Wellcome Trust as well as the Bill and Melinda Gates Foundation-funded PERCH project.
LUXEMBOURG BIOHEALTH CAPABILITIES
35
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Philippe Sollie CREATION DATE 2011 EMPLOYEES 0-9 TRADING AREA International INTERNATIONAL LOCATIONS Europe
CORE BUSINESS Flen Pharma is an international group that was established in November 2000 in Belgium, building on the results of wound-treatment research performed in the 1990s by its Managing Director Philippe Sollie, a pharmacist. Flen Pharma is a privately owned company. Its products for wound healing are based on the moist-wound healing principle and originate from patented polymer applications and patented enzyme complexes.
PRODUCTS & SERVICES Flen Pharma’s products — Flaminal® Hydro, Flaminal® Forte, Flamigel®, Extracalm® and Flamirins® — are registered within the EU as well as in China, Switzerland and Saudi Arabia. Its first line of products is in wound care. New products are in development in dermatological and related fields.
ADDRESS 29, rue Henri Koch L-4354 Esch-sur-Alzette CONTACT Philippe Sollie Tel: +352 26 34 06 27 1 philippe.sollie@flenpharma.com WEBSITE www.flenpharma.com
36
LUXEMBOURG BIOHEALTH CAPABILITIES
Flen Pharma S.A.
LUXEMBOURG BIOHEALTH CAPABILITIES
37
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Glenn Lawyer CREATION DATE 2015 EMPLOYEES 0-9 TRADING AREA International
ADDRESS 9 avenue des Hauts Fourneaux L-4362 Esch-sur-Alzette CONTACT Dr Glenn Lawyer Tel: +352 661 96 72 44 glenn@health-cast.com WEBSITE www.health-cast.com
38
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS The vision of Healthcast is to make public health information accessible to the general public. Healthcast will provide epidemic forecasts, like a weather forecast, informing people of current and upcoming disease situations. If you get sick, Healthcast will also provide you with tools that help you find detailed information on how to provide good care.
PRODUCTS & SERVICES Healthcast combines epidemic surveillance with symptom management. The company applies advanced algorithms which combine clinical, climate and on-line data to keep you informed of current and coming disease threats. It supplies a care management tool which helps you track your symptoms, follow best practice guidelines and shows your symptoms in the context of current conditions. It also pays much attention to the security and privacy of customer health records.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS The Healthcast team is dedicated to continual improvement of the scope, specificity and accuracy of its epidemic forecast engine through the development of new models, expanded data sources and fuller integration with client needs and requests. In addition, it is always enhancing the medical knowledge base which powers its automated parsing of on-line resources and its interpretation of symptomatic data.
Healthcast
TECHNICAL / TECHNOLOGICAL CAPABILITIES Healthcast combines deep knowledge of mathematical epidemiology, development and management of complex medical database systems and cryptography/privacy technologies.
TECHNICAL MEANS / EQUIPMENT The Healthcast team specialises in developing and implementing algorithms with transformative effect on public health.
MAIN CUSTOMERS / COLLABORATIONS Healthcast is well connected with health related research institutes in Luxembourg and Germany. It collaborates with the Luxembourg Institute of Health (LIH), the Max Planck Institute in Saarbrucken and the Luxembourg Institute of Science and Technology (LIST). The main customer of the Healthcast is the general public.
LUXEMBOURG BIOHEALTH CAPABILITIES
39
P R I VAT E S E C TO R PUBLIC RESEARCH
DIRECTEUR GENERAL ADJOINT Christian Oberlé EMPLOYEES 200< TRADING AREA Europe
CORE BUSINESS Hôpitaux Robert Schuman were created in 2014 following the merger of Clinique Bohler, Hôpital Kirchberg, ZithaKlinik and Clinique Sainte-Marie. 250 private doctors and more than 2,200 salaried staff are committed to providing high-quality care and personalised service with a distinctive human touch. Hôpitaux Robert Schuman are organised around seven specialised sections: • the Women’s Clinic and Mother-Baby hub including specialities such as obstetrics, gynaecology, neonatology, in vitro fertilization, etc.; • the geriatric medicine hub; • the psychiatry hub including adult psychiatry and the national juvenile psychiatry service;
ADDRESS Hôpitaux Robert Schuman 9, rue Edward Steichen L- 2540 Luxembourg
• the internal medicine hub including numerous specialities such as cardiology, neurology, nephrology-dialysis, endocrinology or diabetology, etc.;
CONTACT Bistra Atanasova / Tsvetelina Ivanova Tel: +352 24 68 20 39 / +352 24 68 20 40 bistra.atanasova@ hopitauxschuman.lu / tsvetelina. ivanova@hopitauxschuman.lu
• the visceral oncology hub including gastroenterology, gastroenterological and vascular surgery, thoracic surgery and respiratory medicine, urology and medical oncology; and
WEBSITE www.hopitauxschuman.lu www.hkb.lu www.cbk.lu www.zithaklinik.lu www.csm.lu
• the locomotor system hub including orthopaedic specialities, traumatology and rheumatology;
• the “Head and neck” hub including ophthalmology, ear-nose-throat, dental surgery and maxillofacial surgery. Hôpitaux Robert Schuman have a modern structure to meet the needs of the healthcare professionals and ensure the best possible care of the patients. Academic and research roles complement clinical missions of the hubs.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Hôpitaux Robert Schuman are strongly engaged in health education using preferently new tools that emerge in health informatics and Internet. Thus the creation of the first e-learning website in the area of Gynecology-Obstetrics in 2011 was the first milestone in the creation of an e-learning platform that will eventually cover all the centres of expertise of Hôpitaux Robert Schuman. A global e-learning platform dedicated to patients is an essential component in the efforts to involve patients in playing an active role in the upholdling of their health reserves. The e-learning webspace is a global platform for patients, dedicated to the transfer of new knowledge using multimedia tools. It currently includes platforms in the areas of Obstetrics and Gynecology (www.cbk-learning.lu), Psychiatry (www.psylearning.lu) and Orthopedy (www.ortho-learning.lu). The e-learning webspace is the result of a user-centered approach and responds to patients’ need of accessible, highly reliable information. It offers a time/cost saving solution by reinforcing the teachings given by the staff and doctors to patients. All its contents are developed and reviewed by medical professionals. This educational platform has great resource sharing and co-development potential. CBK-learning.lu is a unique e-learning platform for preventive women’s healthcare, health education and an effective support tool for future parents through multimedia technologies. PSY-learning.lu is the first e-learning site in Luxembourg dedicated to patients and their family in terms of prevention and treatment of mental illness. It is a psycho-
40
LUXEMBOURG BIOHEALTH CAPABILITIES
Hôpitaux Robert Schuman
educational teaching tool available to everyone, dealing initially with the subject of depression (other topics are currently being developed). ORTHO-learning.lu is the first e-learning site in Luxembourg dedicated to patients and their family in relation to the treatemenet of illness related to the musculoskeletal system. Its first topic is hip replacement. Advantages: • for patients: high quality contents and interactive resources; flexibility and easy access to contents; • for nurses: better deal with time pressure and patients’ need for health education; contents relying on evidence based learning; based on FAQs gathered during patient discussion groups; • for physicians: validation of the contents by an expertee committee composed of medical and paramedical staff; • for CEO&CFO and HR: a time/cost saving solution in today’s context of resources limitation; a powerful tool tackling several issues simultaneously: patient education, up-to-date and consistent nursing guidelines fo the staff, involvement of personnel/doctors for content production; • for marketing: leverage for internet visibility; high potential for personalised service development. The e-learning solution enabled us to respond to a series of challenges: • establish early contact with the patient base; • develop modern communication channels and innovative training; • be accessible and available to customers whatever their geographic distance to the hospital; • provide consistent information and quality education before, throughout and after the patient’s hospital stay; • anticipate patient questions, needs and concerns. The e-learning webspace follows a quality charter regarding the medical validity of the content (evidence based learning), the educational tools and regarding the quality of technical, graphic and visual media used.
• virtual tours; • advanced user management;
TECHNICAL / TECHNOLOGICAL CAPABILITIES
• newsletters;
Features of the e-learning platforms:
• CDN hosting architecture;
• visual approach with contrasted colours as to emphasise important screen areas for the user;
• dynamic glossary; and • patient testimonials and much more.
• 200+ validated detailed info sheets; • modern and comfortable user-oriented webdesign; • responsive design, one-to-one oriented features; • live interactive sessions; • serious games; • educational interactive videos;
MAIN CUSTOMERS / COLLABORATIONS The group presently works with several partners (currently German and Belgian ones) that help to further develop the contents of the platform in exchange for using the contents for their own purposes. The aim is to develop a partner network in the context of European or local funding programmes.
• quizzes; LUXEMBOURG BIOHEALTH CAPABILITIES
41
P R I VAT E S E C TO R PUBLIC RESEARCH
CO-OWNER AND ADMINISTRATOR Jean-Paul Scheuren CREATION DATE 2012 EMPLOYEES 0-9 TRADING AREA International
ADDRESS 29, rue Henri Koch L-4354 Esch-Sur-Alzette CONTACT Jean-Paul Scheuren Tel: +352 621 15 30 83 info@houseofbiohealth.lu WEBSITE www.houseofbiohealth.lu
42
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS The House of Biohealth is a unique facility where research meets business in an atmosphere that favours communication and exchange. The overall infrastructure, including the meeting areas, the conference facilities as well as the restaurant are designed to ensure that tenants can concentrate on their core activity. The House of Biohealth is more than a building; it is a real opportunity for tenants to develop their activity in a dynamic scientific, economic and cultural environment.
PRODUCTS & SERVICES Research and laboratory facility for biotechnology, ICT and cleantech Renting conditions defined in tailor-made solutions
House of Biohealth Innovation Cluster 1 sĂ rl
TECHNICAL MEANS / EQUIPMENT 9,500 m2 of laboratory space (modules of 150 sqm) to rent 7,800 m2 of office space, conference and communication
MAIN CUSTOMERS / COLLABORATIONS All innovative companies searching for an inspiring workplace.
LUXEMBOURG BIOHEALTH CAPABILITIES
43
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Michel Witte CREATION DATE 1989 EMPLOYEES >250 TURNOVER 2012 €160,000,000 TRADING AREA International R&D INTERNAL INVESTMENTS 2012 €16,000,000 CERTIFICATIONS, QUALIFICATIONS, ISO 9001, ISO/TS 16949, OHSAS 18001, ISO 14001 INTERNATIONAL LOCATIONS Europe, North America, South America and Asia
CORE BUSINESS IEE is a global leader in automotive safety sensing systems for occupant detection and classification with products such as OC™, BodySense™, Seat Belt Reminders and Protecto™, enhancing safety in vehicles produced by major car manufacturers worldwide. IEE’s Tailgate Detector, People Counter and Volumetric Object Surveillor are implemented in public and commercial infrastructure to enhance building security and automation. These solutions are based on the company’s innovative 3D MLI Sensor™ technology. IEE’s sensing systems are dedicated to the following markets: Transportation & Automotive, Public & Commercial Infrastructure, Consumer, and Medical & Healthcare.
PRODUCTS & SERVICES Automotive sensing: • Seat Belt Reminder (SBR); • Occupant Classification (OC™); • Protecto™; • BodySense™; • Driver Presence Detection (DPD); • Customised HMI; • SenseAhead. People and object sensing for building management and security:
ADDRESS 16, rue de la Libération L-7347 Steinsel CONTACT Aloyse Schoos Tel: +352 24 54 1 iee@iee.lu WEBSITE www.iee.lu
• People Counter; • Tailgate Detector TDflex™; • Volumetric Object Surveillor.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS • Wearable, wireless-connected, ventilation monitoring system and method for performance assessment and for supporting the rehabilitation of breathing impaired patients; • wearable, wireless-connected, sensing system for smart orthotics (check of the regular usage combined to the tracking of the patient activity); • wearable, wireless-connected foot pressure monitoring system for rehabilitation and prevention purposes (diabetes foot complications, orthopaedic and podiatry diagnosis, fall detection, etc.); • optical technology for remote vital signs monitoring and drowsiness assessment.
44
LUXEMBOURG BIOHEALTH CAPABILITIES
IEE S.A.
TECHNICAL / TECHNOLOGICAL CAPABILITIES • Customer programme engineering and support; • electronics development; • material development; • semiconductor development; • algorithmics & embedded software development; • development of optical systems; • simulation-based development (virtual engineering); • a full-scale product testing laboratory.
TECHNICAL MEANS / EQUIPMENT • Dynamic Mechanical Analyser (DMA); • Thermo-Gravimetric Analyser (TGA) that includes mass spectrometer (MS) coupling; • Differential Scanning Calorimeter (DSC); • Fourrier-Transform Infrared Spectrometer (FTIR); • Universal Material Test System that covers temperatures from -150°C to +250°C; • Optical and Mechanical Surface Analyser; • Climatic / Environmental testing; • EMC testing.
MAIN CUSTOMERS / COLLABORATIONS Aéroports de Paris, Alfa Romeo, American Access Control, Audi, Bang & Olufsen, Bentley, BMW, BOSE, Cadillac, Chrysler, Delphi, Faurecia, Ferrari, Fiat, Ford, General Electrics, GM, Great Wall, Hyundai, Jaguar, Land Rover, Magna, Maserati, Mercedes-Benz, Mitsubishi Motors, Motorola, Nissan, Opel, Pininfarina, Porsche, PSA, Recaro, Renault, Rolls-Royce, Saab, Samsung, Scenetap, Seat, Siemens Building Technologies, Skoda, Suzuki, Tachi-S, TATA, Toyota, Valeo, Vauxhall, Volkswagen, Volvo.
LUXEMBOURG BIOHEALTH CAPABILITIES
45
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Jean-Marie Saint-Remy R&D INTERNAL INVESTMENTS 2012 Patent application costs: ± €80,000
ADDRESS 80, rue des Romains L-8041 Strassen CONTACT Jean-Marie Saint-Remy Tel: +32 16 85 26 31 jeanmarie.saint-remy@med. kuleuven.be
ImNate
CORE BUSINESS The core business of ImNate Sàrl is based on newly discovered mechanisms by which proteins interact with the innate immune system. These mechanisms now provide opportunities to develop new medicines for the treatment of a large number of human or animal diseases. In fact, ImNate technology can be described in terms of two types of therapeutic development: • new methods for the prevention of unwanted immune responses associated with disease processes or elicited by exposure to environmental agents, including therapeutic agents; and • new methods for the modulation of immune responses, namely increasing or suppressing responses depending on the setting.
PRODUCTS & SERVICES Products: overall, ImNate will provide medicines for the treatment of human or animal diseases for which there is presently no, or only limited, therapeutic possibilities. Fields include the production of genetically-modified proteins (e.g. gluten in the prevention of celiac disease), allofactors used for therapeutic purposes (e.g. coagulation factors), viral vectors for use in gene therapy and gene vaccination, vaccines to eradicate infections, suppress tumour expansion, as well as proteins for vaccination towards allergens. ImNate will also provide services to partners involved in the production of therapeutic agents with no, or limited, capacity to elicit an immune response in the host.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS ImNate technology provides six main opportunities: • prevent disease development by providing natural proteins with reduced immunogenicity. Examples are the production of genetically modified organisms to prevent celiac disease or food allergic sensitisation; • prevent unwanted responses to therapeutic agents such as therapeutic antibodies or to coagulation factors or hormones in patients suffering from deficiencies; • open the way towards application of novel therapies, the best example of which is gene therapy and gene vaccination, which virtually opens the way to hundreds of applications both for the replacement of a missing or dysfunctioning gene and for efficient vaccination towards viruses such as HIV; • make vaccination (more) effective to weak immunogens, such as allergens, or to organisms diverting the host immune response; • provide a novel approach to target tumours through activation of cells specific for tumor-derived antigens; • provide a novel approach to control auto-immune diseases.
46
LUXEMBOURG BIOHEALTH CAPABILITIES
ImNate S.à r.l.
TECHNICAL / TECHNOLOGICAL CAPABILITIES The technology is based on the production of peptides or polypeptides made by either chemical synthesis or recombinant technology. Peptide production can easily be outsourced if required, as there a number of companies offering this service. Peptides for therapy will be administered together with an adjuvant such as alum. Proteins considered for therapy would essentially be produced by either companies involved in their production, or, when proteins are in the public domain, it can be envisaged to produce it from own resources.
MAIN CUSTOMERS / COLLABORATIONS ImNate provides a platform technology with a large number of possible applications. Collaborations are therefore looked at from different angles of view. Depending on the field involved, ImNate would consider: • license agreements with an established company; • service agreements with an established company; • collaborations established with public or private funding support; • development on own resources by, for instance, the creation of a new entity.
LUXEMBOURG BIOHEALTH CAPABILITIES
47
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Andreas Kremer CREATION DATE 2015 EMPLOYEES 0-9 TRADING AREA International INTERNATIONAL LOCATIONS Greater Region
ADDRESS 9, avenue des Hauts-Fourneaux L-4362 Esch-sur-Alzette CONTACT Dr Andreas Kremer Tel: +352 54 55 80 305 andreas.kremer@ittm-solutions. com WEBSITE www.ittm-solutions.com
CORE BUSINESS ITTM (Information Technology for Translational Medicine) S.A. is a spin-off company of the Luxembourg Centre for Systems Biomedicine (LCSB) and is set-up to satisfy a growing demand of both pharmaceutical and biotech companies, public research institutions and private foundations in the field of translational medical research. ITTM S.A. provides data integration and knowledge management solutions and services to all bio-medical research areas. It focuses especially on translational medicine studies and clinical trials, in which heterogeneous data need to be curated, linked and integrated. ITTM S.A. provides cutting-edge clinical and multiomics data analysis, visualisation and text-mining solutions.
PRODUCTS & SERVICES One of the biggest challenges in the field of translational medicine in pharma and biotech industry is the integration of heterogeneous data generated in multi-centre clinical trials and via multi-layer lab measurements especially in clinical environments. Curation, harmonisation and mapping of retrospective and prospective clinical data, omics and imaging data are key solutions for this challenge. The services that are offered by ITTM S.A. help these stakeholders to make use of biological and medical data sets that are not accessible to standard data analysis due to their complexity and variability, seeking for new insights into disease progression, patient stratification, safety interpretation, biomarker discovery and disease taxonomic classification. Uniquely, all services and data will be hosted in a state-of-the-art data centre in Luxembourg ensuring highest security standards. ITTM offers comprehensive services in the following fields: • curation and transformation of biomedical data to follow international standards; • analysis of biomedical data and customised software development; • custom software developments for data mining processes and visualisation tools; • hosting of data and access to the query and analysis platform; • archiving and long term storage of data according to legal frameworks.
48
LUXEMBOURG BIOHEALTH CAPABILITIES
ITTM (IT for Translational Medicine) S.A.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS The company founders have long standing experience and expertise in these services due to successful participation and contribution to large translation medicine consortia such as the IMI-eTRIKS (European Translational Information & Knowledge Management Services) and IMIAETIONOMY.
TECHNICAL / TECHNOLOGICAL CAPABILITIES The company offers a highly integrated BioIT (ICT) service portfolio, ranging from data curation and cleansing, hosting of knowledge platforms, implementation and development of dedicated software and data analysis pipelines to final long-term backup and archiving of data.
LUXEMBOURG BIOHEALTH CAPABILITIES
49
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Stéphane Gidenne EMPLOYEES 100-249 TRADING AREA Europe CERTIFICATIONS, QUALIFICATIONS, ISO Norm 15189 INTERNATIONAL LOCATIONS Europe
CORE BUSINESS With an average of 16,500 nomenclature codes per day, Ketterthill is the biggest private medical laboratory in the Grand Duchy of Luxembourg. Composed of 204 employees, including 7 medical biologists (MD and pharmacists) originating from the hospital as well as the private sector, the laboratory performs so-called routine tests in the fields of hematology, chemistry, endocrinology, serology, microbiology, spermiology and autoimmunity. Especially concerning the autoimmunity, the laboratory is recognised for its expertise and receives samples from all over Europe. The laboratory is accredited according to the ISO Norm 15189 in all areas since 2009. It also participates actively in promoting bone marrow donation in partnership with the Luxembourg Bone Marrow Transplant. Moreover, its biologists participate in international conferences (oral presentations, posters, articles).
PRODUCTS & SERVICES The Ketterthill laboratory is present all over Luxembourg with 65 collection centres and sampling points. In addition, the laboratory offers support for home blood sampling and care homes.
ADDRESS 8, avenue du Swing L-4367 Belvaux CONTACT Dr Sylvie Coito Tel: +352 48 82 88 313 sylvie.coito@ketterthill.lu WEBSITE www.llam.lu
• The laboratory has currently the 3rd GLP track in the world, measuring 200 metres on 3 floors. 19 analyzers are connected. This new track reduces the waiting period for lab reports and allows technicians and biologists to contribute with their expertise to all files. • The Ketterthill laboratory works closely with physicians of the Grand Duchy exchanging information for optimal result interpretation and care of patients. Urgent requests are processed and communicated as quickly as possible. Biologists regularly write newsletters to keep prescribers informed about the newest developments. • The laboratory cooperates with other local laboratories as well as with foreign laboratories, in particular for special requests. • In addition, the laboratory participates actively in promoting marrow donation in partnership with Luxembourg Bone Marrow Transplant and the German Foundation Stephen Morch. Therefore, it won the European CSR Award, rewarding the partnership between an association and a company in a joint project with an impact on society. Ketterthill’s actions can vary from blood sampling to writing flyers to lectures on the subject. • Ketterthill promotes innovation in the country through its participation in scientist projects with the University of Luxembourg in medical fields such as Parkinson’s disease or celiac disease. • Finally, Ketterthill’s biologists publish popular articles (ANIL newspaper), scientific articles, attend international conferences (oral presentations, posters), and participate in international scientific conferences.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS • Routine analysis (analysis catalogue on www.llam.lu); • expert analysis in auto-immunity (more than 80 autoantibodies tests); • consulting services for physicians (comments, telephone contact, advising); • participation in expert groups for the Belgian EEQ (ISP) and French EEQ (biologie prospective);
50
LUXEMBOURG BIOHEALTH CAPABILITIES
Ketterthill
• reactive testing in autoimmunity area before production (Society Rugwag); • equipment testing (PhD of Bio-Rad, blue diver of D-Tek, etc.); • training of physicians; • study EHES: epidemiological study of more than 2 years; • e-santé project (DSP); • committee of Microbiology in 14 CEL members lab group and committee of autoimmunity; • medical hygiene: audit, continuous training and analysis for infectious diseases monitoring and nosocomial risks; • scientific projects with the University of Luxembourg; • expertise for the University Hospital (Leuven (BE), Strasbourg (FR) etc., or customers (Thermofischer, Medarini, etc.).
TECHNICAL / TECHNOLOGICAL CAPABILITIES With the equipment described below, Ketterthill lab has the capacities to performe the majority of the routine analyses and the ability to realise the latest tests in auto-immunity, especially concerning neurological auto-antibodies.
TECHNICAL MEANS / EQUIPMENT • Microbiology: BD Kiestra line, Vitek (BioMérieux), IQ-Velocity (Iris Coulter), Spectrometry of masse (Maldi Tof Brüker), Real time PCR (BioRad); • Hormono-Chemistry-Serology-Hormonology: Abbott line (Phadia 1000, C16000, I2000), Etimax (Diasorin), Hydrasis (Sebia); • Hematology: HN Sysmex line (SP10, DM96), Coagulation CS5000 (Siemens); • Immunohematology: Autovue (Ortho), Tosoh G8, Halifax; • Auto-immunity: PhD (BioRad), Etimax (Diasorin), Helmed (Aesku Diagnostics Systems), Profiblot 48 (Tecan), Manual techniques; • Spermiology: manual techniques.
MAIN CUSTOMERS / COLLABORATIONS Prescribers, LNS, CHL, CHEM, Hôpital du Nord, Croix-Rouge Luxembourgeoise, LIH, LCSB, LIST, FLLAM, MLQ, Association Don de moelle, ANIL, LluCS, Mondorf Domaine Thermal, FEDIL, clc, Charte de la diversité, Luxembourg Air Rescue, e-santé, Cerba, Biomnis, university hospitals Company providers: reagent test Member of SLGO (Society Luxembourg Gynecology Obstetrics), of SLAM (Society Luxembourg Andropause Menopause), GEAI (Study group of Autoimmune Diseases) LUXEMBOURG BIOHEALTH CAPABILITIES
51
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Prof. Dr med Bernard Weber CREATION DATE 1996 EMPLOYEES 100-249 TRADING AREA International
CORE BUSINESS Laboratoires Réunis (LR) is the largest independent private laboratory for medical analyses in the Grand-Duchy of Luxembourg. The headquarters are located in Junglinster where all the analyses are carried out to international quality standards. It was the first laboratory for medical analysis in Luxembourg to be ISO 15189 accredited and it has been distinguished with the national Quality Award labelled “Sur la Voie de l’Excellence”. The activities of LR cover almost the entire domain of clinical biology and microbiology. A part of its activities are focused on applied research, especially in the domains of genetics, microbiology and infectious diseases. LR also carries out special analyses in the field of preventive medicine and of chronic functional diseases. LR gets samples from all over the world.
PRODUCTS & SERVICES ADDRESS 38, rue Hiehl - Z.A.C. Laangwiss L-6131 Junglinster CONTACT Dr Martin Schöndorf Tel: +352 78 02 90 1 contact@labo.lu WEBSITE www.labo.lu
Laboratoires Réunis has developed a nationwide network of 50 blood withdrawal centres. Blood withdrawal services are also offered at home and in companies. Molecular diagnostics of infectious diseases — LR provides a large catalogue of analyses based on multiplexed Real-Time-PCR and development of new diagnostic assays in cooperation with Fast-track Diagnostics (FTD) Luxembourg. Preventive genetic tests — to improve health in terms of nutrition, lifestyle and treatment. Environmental medicine: • detection and identification of fungi and mould (which have an environmental impact) in the surroundings of the patient (in collaboration with the Association Luxembourgeoise de Médecine de l’Environnement (ALMEN) and the Luxembourg Ministry of Health); • genetic profiling of the individual detoxification capacities; • stool flora scan (SFS); comprehensive assessment of the gut ecology and immunity; • imuPro; identification of type III food intolerances; • MELISA; identification of heavy metal allergies; • assessment of oxidative stress and antioxidative capacities of the human body.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS International cooperation in preventive medicine with healthcare practitioners, laboratory testing services, distributors and medical spas. Collaboration for clinical studies with international in-vitro-diagnostic companies. Laboratoires Réunis actively contributes to applied research on clinical studies in the field of microbiology in collaboration with the universities in Frankfurt and Glasgow, as well as on genetic research in collaboration with the University of Homburg-Saar.
52
LUXEMBOURG BIOHEALTH CAPABILITIES
Laboratoires Réunis
TECHNICAL / TECHNOLOGICAL CAPABILITIES • Fully automated analysis of most routine parameters; • clinical chemistry, hematology, hemostasis, immunology, microbiology, virology, etc.; • real-time PCR; • multiplexed PCR; • mass spectrometry.
TECHNICAL MEANS / EQUIPMENT Analytical chain for clinical routine analysis.
MAIN CUSTOMERS / COLLABORATIONS • National & international health care providers´; • Laboratoire National de Santé; • Laboratoire Luxembourgeois de Contrôle Sanitaire (LLuCS); • Ministry of Health; • Luxembourg Institute of Health (LIH); • Deutsches Zentrum für Individualisierte Prävention und Leistungsverbesserung (DZIP); • Advanced Biological Laboratories (ABL).
LUXEMBOURG BIOHEALTH CAPABILITIES
53
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Paul Fenton CREATION DATE 2005 EMPLOYEES 10-49 TRADING AREA International INTERNATIONAL LOCATIONS Europe, North America
ADDRESS 507, Place d’Armes, Suite 1050 Montreal QC, H2Y 2W8, Canada CONTACT Valérie R. Paradis Tel: +1 51 42 23 91 53 218 vparadis@montrium.com WEBSITE www.montrium.com
54
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS Montrium is a knowledge-based company that focuses on leveraging its deep understanding of GxP processes and technologies to provide cost-effective solutions to life science organisations. Montrium’s industry leading SharePoint solution, Montrium Connect, offers a truly collaborative and compliant document and quality management environment in the cloud or on premise. At Montrium, we believe in providing the best possible products and services for our customers. Our ability to understand the sometimes complex needs of our clients is the reason why our clients return to us every time. We work together as a team to always put our customers first, focusing on close collaboration between our clients and our team members. Our transparent approach towards any new opportunity has allowed us to create bonds of trust with some of the largest players in the life sciences industry. We will continue to take this ethos into every new project we gain ensuring that our performance and our dedication do not falter. Montrium is a Microsoft Gold Partner which means that our team is certified in the development and deployment of solutions based on SharePoint and other associated technologies. In addition to our Montrium Connect solution, we also provide a series of different services and documentation packs to help our clients deploy regulated SharePoint environments for GxP applications. We have significant expertise in the implementation of electronic environments for clinical R&D and pharmaceutical manufacturing and offer a full range of services to help companies plan, select, implement and validate regulated systems for the life sciences.
Montrium S.A.
PRODUCTS & SERVICES Montrium’s competitive advantage rests in the quality of its service, responsiveness to customer needs, scope of international knowledge and dedication to providing superior, timely, cost-effective and valueadded solutions to customer problems in pharmaceutical development. The company focus on helping life science companies select, implement and validate computerised systems for GxP environments. Through a combination of its knowledge of GxP processes and experience in system implementation, it is able to bring enhanced value to our clients. Montrium’s team of experts build on a broad depth of industry expertise to implement solutions that meet the needs of today’s evolving and changing pharmaceutical landscape. Through the use of collaborative SharePoint technology, Montrium is able to automate and optimise project execution. With strong focus on knowledge transfer, its clients’ needs are captured at every step of the implementation process when following a holistic approach to project management. The company takes a lean, risk based end-toend approach to reduce the time and complexity associated with the implementation of validated systems which in turn maximizes ROI.
MAIN CUSTOMERS / COLLABORATIONS Clients include, among others, Aptalis, DSM Sinochem Pharmaceuticals, Ironwood, Clindatrix, EORTC, Datatrial, IDDI and Sotio.
LUXEMBOURG BIOHEALTH CAPABILITIES
55
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO François Scalais CREATION DATE 2009 EMPLOYEES 0-9 TURNOVER 2013 €300,000 TRADING AREA Europe R&D INTERNAL INVESTMENTS 2013 €500,000 CERTIFICATIONS, QUALIFICATIONS, Authorised Private Research Centre (since September 2013) INTERNATIONAL LOCATIONS Greater Region
ADDRESS 14 rue Aldringen L-1118 Luxembourg CONTACT François Scalais Tel: +352 26 20 34 02 francois.scalais@neoms.com WEBSITE www.neoms.com
56
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS Neo Medical Systems S.A. acts as a medical devices distributor and private research centre. We provide and install surgical operating rooms equipment in Belgium and Luxembourg. The company’s R&D division develops, designs and manufactures OEM Tracking Solutions for the surgical market and more precisely for glasses-free 3D FULL-HD laparoscopic surgeries.
PRODUCTS & SERVICES OEM Surgical Head-Tracking Systems for Medical Display Manufacturers Surgical Operating Tables (Distribution) Surgical Operating Lights (Distribution) 3D and 2D Laparoscopic camera and medical display (Distribution) High-Definition Medical Acquisition and/or Integrated Systems (Distribution)
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS New Medical Systems’ development team develops and designs extremely fast, powerful, reliable and accurate surgical tracking systems to be used in complex environments like a surgical room.
Neo Medical Systems
TECHNICAL / TECHNOLOGICAL CAPABILITIES The companyâ&#x20AC;&#x2122;s tracking systems are able to detect and track even in complex conditions: in complete darkness, at long distance (up to 3 metres) and even while wearing eyeglasses, a surgical mask and a surgical cap.
MAIN CUSTOMERS / COLLABORATIONS Neo Medical Systems works in close collaboration with DFKI, German Research Center in Artificial Intelligence.
LUXEMBOURG BIOHEALTH CAPABILITIES
57
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO David Sibaud CREATION DATE 2007
CORE BUSINESS Simeda is an expert in the development and manufacture of complex dental and medical prostheses in zirconium oxide (technical ceramic), titanium and Chrome Cobalt.
EMPLOYEES 10-49
In the dental field, which is its core business, Simeda markets a totally digitised production system comprised of scanners that enable 3D mapping of the prostheses environment and design software for prosthetics modelling. Digital files are sent to Simeda for the machining process.
TURNOVER 2012 €2,200,000
PRODUCTS & SERVICES
TRADING AREA Europe
Implant or tooth prosthetic restorations: frames, abutments, suprastructures, overdentures
CERTIFICATIONS, QUALIFICATIONS, ISO 9001, IS0 13 485
Wide choice of materials: zirconium, titanium, cobalt chromium, Peek, PMMA Complete certified mastery of production, design and industrialisation A truly open CADCAM solution for all laboratories An international team of experts at the production site in Luxembourg
ADDRESS 18 Op der Sang L-9779 Eselborn CONTACT Julien Bieber Tel: +352 26 64 04 1 j.bieber@simeda-medical.com WEBSITE www.simeda-medical.com
58
LUXEMBOURG BIOHEALTH CAPABILITIES
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Shape optimisation model for components made of brittle materials Intra oral scanning — optical print
Simeda
TECHNICAL / TECHNOLOGICAL CAPABILITIES Apart from the mechanical expertise involved in medical prostheses machining and associated equipment, Simeda specialises in reverse engineering techniques, which enable 3D mapping and digitisation of the prostheses environment for dental applications. Simeda uses and markets scanners specifically designed for these applications and offers design software developed from specifications drawn up in response to the requirements of prosthesists and dental surgeons worldwide. Both standard repair work and implant work are possible using this software. Simeda produces and provides its own zirconia in order to master the complete chain, from the raw material to the finished parts.
TECHNICAL MEANS / EQUIPMENT Simeda is equipped with latest generation 5-axes machining centres, enabling the production of complex and precise prostheses and associated equipment in zirconium, titanium, CoCr and resin. Simeda also uses athe laser sintering technology that allows the realisation of CoCr prostheses by adding material (CoCr powder sintered by a laser beam). Simeda also has proven expertise in reverse engineering, particularly due to mastery of photogrammetry and white-light-ray projection techniques.
MAIN CUSTOMERS / COLLABORATIONS EU dental laboratories Implant companies Universities
LUXEMBOURG BIOHEALTH CAPABILITIES
59
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Andreas Laschke CREATION DATE 1988 EMPLOYEES 100-249
CORE BUSINESS Development, manufacturing and sales of diaphragm valves, non-return valves and actuators for valves.
PRODUCTS & SERVICES • Diaphragm valves for sterile applications; • diaphragm valves and non-return valves for Industry and energy applications;
TURNOVER 2014 €17,100,000 TRADING AREA International CERTIFICATIONS, QUALIFICATIONS ISO 9001:2008, ISO 14001:2004, BS OHSAS 18001:2007, AD2000 / DIN EN ISO 3834, KTA 1401, HAF604, Instructions 97/23 EG Modul-H, SuperDrecksKëscht INTERNATIONAL LOCATIONS Greater Region
ADDRESS Zone Industrielle L-6468 Echternach CONTACT Andreas Laschke Tel: +352 32 50 85 1 andreas.laschke@ksb.com WEBSITE www.sisto.lu
60
LUXEMBOURG BIOHEALTH CAPABILITIES
• diaphragm valves for building services; • special valves for nuclear applications.
SISTO Armaturen S. A.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Supply of sterile diaphragm valves and accessories for SANOFI Frankfurt, ROCHE Penzberg, LONZA Visp and Kourim, BAXTER Singapore and FRESENIUS St.Wendel and others.
TECHNICAL / TECHNOLOGICAL CAPABILITIES Excerpt: Development of any kind of valves and accessories. Machining of complexe metal structures. Special stainless steel and alloys surface treatment including electropolishing. Hard and soft rubber lining. PTFE lining. ECTFE or PA-coating. Development, testing and production of diaphragms. High level quality assurance and documentation systems.
LUXEMBOURG BIOHEALTH CAPABILITIES
61
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Roman Elsen CREATION DATE 1998 EMPLOYEES 10-49 TRADING AREA International
ADDRESS 23, Am Scheerleck L-6868 Wecker CONTACT Roman Elsen Tel: +352 26 71 66 0 r.elsen@te-gl.eu WEBSITE www.te-gl.eu
62
LUXEMBOURG BIOHEALTH CAPABILITIES
CORE BUSINESS T&E Gefahrgutlogistik AG is a global service provider for the logistic business specialised in handling dangerous substances and goods as well as in advice regarding the respect and implementation of national and international regulations. The company supports our international clients in all fields of transportation, packing, stocking and handling of dangerous substances / goods and waste products for industrial customers and the medical sector.
PRODUCTS & SERVICES T&E Gefahrgutlogistik focuses on the handling of dangerous goods for all means of transportation. The company develop tailored and legally compliant solutions for the packing of dangerous goods. The companyâ&#x20AC;&#x2122;s main focus is on the handling of dangerous goods in the field of hospital logistics. This includes the set-up of storage facilities for dangerous substances and authorisation procedures for laboratories and hospitals as well as the handling and transportation of infectious substances, medical samples and laboratory chemicals. T&E Gefahrgutlogistik also offers a complete and tailor-made range of training on dangerous substances and goods. The company can put an external risk prevention officer at clientsâ&#x20AC;&#x2122; disposal. T&E Gefahrgutlogistik offers a 24-hour hotline for emergencies with regard to dangerous goods and related questions.
T&E Gefahrgutlogistik AG
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS T&E Gefahrgutlogistik’s specific knowledge is asked for by administrations and public research institutes as well as by our customers. Jointly with partners such as the Luxembourg Insitute of Science and Technology (LIST), it is incorporated in trend-setter projects such as “DG-Trac — Support of dangerous goods transport in the medical sector”.
TECHNICAL MEANS / EQUIPMENT The company has access to specialised transportation and packing equipment in conformity with UN regulations for all kinds of dangerous goods.
MAIN CUSTOMERS / COLLABORATIONS T&E Gefahrgutlogistik’s customers are widely spread from industrial customers to hospitals, laboratories and research institutes. It has set up a cooperation with Luxcontrol for trainings on hazardous substances and goods. Luxaviation is our cooperation partner for air transportation of sensitive medical samples. The company is also a member of the Cluster for Logistics.
LUXEMBOURG BIOHEALTH CAPABILITIES
63
P R I VAT E S E C TO R PUBLIC RESEARCH
MANAGING DIRECTOR EUROPE Rolland Carlson, Ph.D, CEO CREATION DATE 2011 EMPLOYEES 0-9 TRADING AREA Europe
CORE BUSINESS WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The ICELL8TM Single-Cell system is a revolutionary platform which can isolate thousands of single cells and process specific cells for analysis, including for Next Generation Sequencing (NGS). The SmartChipTM platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel single-plex PCR for one-step target enrichment and library preparation for clinical NGS. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical and clinical laboratory industries.
PRODUCTS & SERVICES ADDRESS 84, Val Fleuri L-1526 Luxembourg CONTACT Marizela Kulisic, Ph.D (European Training and Demo Centre Manager) Tel: +352 26 970 970 marizela.kulisic@wafergen.com WEBSITE www.wafergen.com
WaferGen Bio-systems is committed to the development of breakthrough technology platforms for single-cell analysis, gene expression, genotyping and NGS which it believes will revolutionise biopharma, diagnostics and life science research. The ICELL8 Single-Cell System can be used to isolate tens of thousands of single cells which can be individually selected for processing using CellSelectTM image analysis software. The system enables running up to eight samples of various cell types and sizes on a single chip. The Seq-Ready™ TE workflow, powered by massively-parallel singleplex PCR technology, is a fast one-step target enrichment and library prep workflow that delivers excellent sequencing coverage for implementation in clinical research labs, who will benefit from improved accuracy and precision. The company’s SmartChip Real-Time PCR System is a next-generation genetic analysis platform for profiling and validating molecular biomarkers. It provides a range of high-throughput capabilities including microRNA, lncRNA and mRNA (gene expression) profiling as well as single nucleotide polymorphism (SNP) genotyping. The Apollo 324™ is the company’s fully-automated, walk-away library preparation solution for whole-genome, target enrichment, and transcriptome NGS applications.
64
LUXEMBOURG BIOHEALTH CAPABILITIES
WaferGen Bio-systems Europe S.à r.l.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS WaferGen Bio-systems is involved in a large number of its customers’ R&D and clinical research projects for which they use WaferGen Biosystems’ technology either in their own laboratories or as services they provide.
TECHNICAL / TECHNOLOGICAL CAPABILITIES At the heart of WaferGen Bio-systems’ SmartChip technology is a chip with 72x72 nanoscale-wells (each of 100 nL), allowing for 5,184 reactions per chip. Highly reproducible results are obtained within sample replicates, across multiple chips and between multiple systems. The 100nl well size ensures superior performance over other platforms. This specific volume provides benefits such as being ideal for singlecell isolation and no pre-amplification needed for gene expression and genotyping applications. Efficient use of the chip format and configuration can also effectively maximize sample throughput and minimize running costs. Flexibility with many different applications and assay/sample formats make it easy to use the platform to fit one’s experimental design. The development of the technology for single-cell analysis, NGS target enrichment, gene expression and genotyping applications demonstrate the utility and flexibility of the platform.
Apollo 324 NGS Library Prep System
MAIN CUSTOMERS /COLLABORATIONS Typically, the companys’ customers are located within the larger life sciences market, including academic research centres, biotech and pharmaceutical companies, clinics and CROs.
MultiSample NanoDispenser
LUXEMBOURG BIOHEALTH CAPABILITIES
65
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Dr Catherine Larue CREATION DATE 2008 EMPLOYEES 10-49 TRADING AREA International CERTIFICATIONS, QUALIFICATIONS, IBBL is ISO 9001:2008 and NF S96-900:2011 certified and seeking ISO17025 accreditation
ADDRESS 6, rue Nicolas Ernest Barblé L-1210 Luxembourg CONTACT Arnaud d’Agostini Tel: +352 26 940 520 communications@ibbl.lu WEBSITE www.ibbl.lu
CORE BUSINESS The IBBL (Integrated BioBank of Luxembourg) Institute is an autonomous not-forprofit institute dedicated to service provision in the biomedical sector. The mission of IBBL is to provide high-quality biospecimens and associated data, foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new healthcare solutions. IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is an autonomous institute, organised within the Luxembourg Institute of Health (LIH).
PRODUCTS & SERVICES As an NF S96-900 (quality of biological resource centres) and ISO 9001 (general quality management) certified organisation that is compliant with ISO 17025 (competence of testing and calibration laboratories), IBBL offers a full range of services to industry, academia and EU consortia. These services include biobanking, sample processing, sample analysis and quality control, biomarker validation, biospecimen proficiency testing and a university biobanking certificate.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS IBBL provides bioservices to its national and international clients working on a wide range of research projects and clinical trials. IBBL also actively supports research projects in the following priority domains: cancer, diabetes, Parkinson’s disease and microbiome. IBBL also conducts its own biospecimen research, investigating the effects of different collection, processing and storage methods on samples and finding methods of improving sample quality and laboratory processes.
TECHNICAL / TECHNOLOGICAL CAPABILITIES • Biobanking Collection kits, sample collection, sample catalogue, sample and data storage, project management. • Sample processing Genomic and circulating DNA extraction, miRNA/mRNA extraction, protein extraction, freeze drying, peripheral blood mononuclear cell (PBMC) extraction, cell sorting, cell culture, lymphoblastoid cell line establishment, liquid and frozen biospecimen aliquoting, tissue block processing, slide and image preparation, tissue microarrays. • Sample analysis and quality control Characterisation and quality control of fluid biospecimens, tissues, cells, nucleic acids, such as qPCR, RIN measurement, cell viability, miRNA/mRNA profiling, sequencing (16rRNA, TruSeq genotyping, HLA genotyping) and many more. • Biomarker validation Pre-analytical validation, analytical validation, clinical verification, method comparison and provision of quality control material.
66
LUXEMBOURG BIOHEALTH CAPABILITIES
IBBL INTEGRATED BIOBANK OF LUXEMBOURG
• Biospecimen proficiency testing Schemes include: DNA/RNA extraction and purity, RNA integrity, DNA/RNA, extraction from whole blood • University Biobanking Certificate
TECHNICAL MEANS / EQUIPMENT Infrastructure for appropriate storage, processing and testing of biospecimens and associated data; advanced technology platforms for genomic analysis.
MAIN CUSTOMERS / COLLABORATIONS IBBL collaborates with partners on biospecimen collection projects, research, industrial projects and provides a full range of services and of samples to clients from academia, industry and EU research consortia. Partners include the five major hospitals in Luxembourg, the Laboratoire National de Santé, Luxembourg Institute of Health (LIH), the University of Luxembourg, the Luxembourg Centre for Systems Biomedicine (LCSB), the International Society for Biological and Environmental Repositories (ISBER), the Breast International Group (BIG), the European Organisation for Research and Treatment of Cancer (EORTC), the CANCERID consortium (IM), the EU Joint Programme Neurodegenerative Disease Research ( JPND) and industrial partners such as Wafergen, BD and QIAGEN.
LUXEMBOURG BIOHEALTH CAPABILITIES
67
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Prof. Dr Rudi Balling CREATION DATE 2009 EMPLOYEES 100-249
ADDRESS University of Luxembourg Campus Belval 6, avenue du Swing L-4367 Belvaux CONTACT Dr Sabine Mosch Tel: +352 46 66 44 64 23 lcsb@uni.lu WEBSITE www.lcsb.lu
CORE BUSINESS The LCSB’s main focus lies in gaining a better understanding of the molecular mechanisms underlying disease, with an emphasis on the pathogenesis of neurodegenerative diseases. New targets for prevention and intervention of neurodegenerative disease and disease pathogenesis will be analysed in the context of complex biological network composition and behaviour and interpreted as perturbations in the homeostasis of physiological networks. Mathematical descriptions of such networks will be generated and used for the modelling and simulation of how diseases develop and how they are influenced by genetic predisposition or by external environmental parameters, such as drugs, nutrition and life style. A core area of the research is dedicated to Parkinson’s disease. Within a systems approach, genetic, molecular and cellular analysis will lead to direct clinical translation, enabled through collaboration with hospitals in Luxembourg and abroad. The detailed examination of pathways involved in Parkinson-related neurodegeneration, whole genome sequencing of families suffering from Parkinson’s disease, identification of anti-neuroinflammatory targets and the analysis of functional dynamics will offer new insights in the pathogenesis of the disease. In the LCSB’s research programme, the experimental analysis of biological systems across different scales is fully integrated with the development of new technologies, i.e. in the area of high-throughput screening devices, single-cell analysis and in the field of mathematical and computational tools such as electronic patient records. The LCSB aims at a highly interdisciplinary environment at the interface of biology, medicine, mathematics and physics, combining biological experimentation with theoretical modelling.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS The main aim of the LCSB researchers is to gain a better understanding of the molecular mechanisms that underlie neurodegenerative diseases. While scientists study several neurodegenerative diseases at the LCSB, Parkinson’s disease is their main focus. Close collaboration with clinicians and patients are of utmost importance. The aim is to contribute to earlier diagnosis and personalised treatment, for instance through its coordinating role in the recently established National Centre of Excellence in Research on Parkinson’s Disease. LCSB researchers who study Parkinson’s disease are striving towards three main goals: • to be able to diagnose Parkinson’s disease at an earlier stage, before motor symptoms occur; • to define subtypes of Parkinson’s disease based on both the patient’s symptoms and the genetic/environmental factors that cause the disease; and • to develop new treatment strategies which are more personalized and more efficient in the treatment of Parkinson’s disease.
68
LUXEMBOURG BIOHEALTH CAPABILITIES
Luxembourg Centre for Systems Biomedicine (LCSB)
TECHNICAL MEANS / EQUIPMENT Systems biology is to a large extend driven by high-throughput and high-content technologies, such as next generation sequencing, transcriptomics, proteomics, metabolomics or imaging. So far, the LCSB has invested in the following specific technology platforms: • high content cell culture screening and imaging facility; • a neuropathology platform that provides in vivo murine model development and assessment for a variety of neurodegenerative diseases; • metabolomics and fluxomics platforms; • the LCSB bioinformatics core facility, which offers access to high performance computing and large data storage; • a zebrafish platform for gene-function analysis and in vivo screening of small molecules; • a mouse facility to study gene-disease relationships in vivo; • a yeast platform for functional genomics studies; and • induced pluripotent stem cell facility for studies on patient-derived cell cultures.
MAIN CUSTOMERS / COLLABORATIONS The LCSB has established strategic partnerships with leading biomedical laboratories worldwide and with all major biological and medical research units in Luxembourg. The centre fosters collaboration with industrial partners and accelerates the translation of fundamental research results into (clinical) applications. Major strategic partnerships include: Institute for Systems Biology (ISB) in Seattle (USA), the Gladstone Institutes in San Francisco, the California Institute of Technology in Pasadena, the University of California in San Diego (UCSD), the Systems Biology Institute (SBI) in Tokyo, the Helmholtz Zentrum München, and EMBL in Europe. In addition, high-level clinical partnerships have been formed with the Hertie Institute in Tübingen, the Paracelsus-Elena-Clinic in Kassel, and the Oxford Parkinson’s Disease Centre (OPDC) who excel through their unique patient cohorts in PD. Luxembourg-based partnerships include: Luxembourg Institute of Health; Centre Hospitalier de Luxembourg (CHL); Integrated Biobank of Luxembourg (IBBL).
LUXEMBOURG BIOHEALTH CAPABILITIES
69
P R I VAT E S E C TO R PUBLIC RESEARCH
CORE BUSINESS CEO Dr Jean-Claude Schmit EMPLOYEES 250< TRADING AREA International CERTIFICATIONS, QUALIFICATIONS Seven LIH units are ISO 90012008 certified since December 2013
ADDRESS 1A Rue Thomas Edison L-1445 Strassen CONTACT Dr Françoise Liners Tel: +352 26 97 02 70 francoise.liners@lih.lu WEBSITE www.lih.lu
The Luxembourg Institute of Health (LIH) is a public biomedical research organisation. Striving for excellence, its researchers, by their creativity, enthusiasm and commitment, generate knowledge on disease mechanisms and contribute to the development of new diagnostics, preventive strategies, innovative therapies and clinical applications that impact the healthcare of Luxembourgish and European citizens. The activities of the Luxembourg Institute of Health are developed within the following research areas: Oncology, Infection and Immunity, and Population Health. At the forefront of biomedical sciences, LIH is deeply involved in implementing national and international research programmes in personalised medicine. It acts as a catalyst for promoting research collaborations with healthcare providers, hospitals and other public and private biomedical organisations. To create economic and societal value, a strong focus is on scientific discoveries and technologic developments. As the prime supplier of public health information in Luxembourg, it also enables public authorities to make decisions based on scientific data and to communicate validated data to international institutions. LIH hosts a large number of trainees, Master students and PhD candidates, affiliated to the University of Luxembourg or to foreign partner universities, as well as postdoctoral scientists specialising themselves in a given research domain. Modern infrastructures, state-of-the-art technologies, trainings and a stimulating work environment are as many elements guaranteeing quality supervision for these young scientists starting their career.
PRODUCTS & SERVICES The research departments of LIH offer expertise and capabilities from which other public research institutions or private partners (e.g. biotech SMEs and pharma companies) can take advantage in their R&D projects. Specific know-how and IPR assets, among others patents, can be made available by the research departments to address fundamental or more applied questions related to their research domains (see section on Major Projects for details). LIH also provides key customised services including: • support for conducting clinical trials and epidemiological studies in Luxembourg; • statistical and methodological advice for the design of R&D projects and clinical studies; • access to a specific pathogen-free animal facility for rodents and biosafety level 3 laboratory of 400 m2; • assistance with confocal microscopy: sample preparation, labelling, microscope operation, image acquisition and analysis including 3D reconstruction and animation; • assistance with analytical, preparative and high-throughput cytometry: experimental design, cell sorting (FACSAria and FACS-Influx), data acquisition and multiparameter analysis (FACS-Fortessa and FACSCanto-up to 18 parameters), and Mass Cytometry (CyTOF-2); • assistance with microarrays, qPCR arrays and NGS: experimental design, extraction, quality control and processing of DNA and RNA samples, microarray development, analysis and interpretation of data;
70
LUXEMBOURG BIOHEALTH CAPABILITIES
Luxembourg Institute of Health Research dedicated to life
• assistance with the identification of biomarkers of environmental exposure of humans to pollutants in biological samples, including hair: experimental design, MS/MS analyses and data interpretation; • assistance with the identification of proteomics-based biomarkers for the diagnosis and/or prognosis of cancers: clinical sample processing, design and performance of high throughput analyses.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Research projects at LIH aim to decipher the mechanisms underlying the development of diseases in order to contribute to the definition of better preventive measures, diagnostic tools and therapeutic solutions. These projects cover mainly the discovery and/or evaluation of: • biomarkers for the diagnosis or prognosis of cardiovascular diseases, lung cancer and allergic diseases; • animal allergens for the diagnosis of patient sensitisation to food and respiratory allergens; • anti-cancer activities of medicinal plant compounds; • therapeutic targets and strategies against cancers such as gliomas and hematological diseases; and • molecules, including peptides, with antiviral potential. They also encompass the development of innovative: • conjugate vaccines against viruses; • resistance and viral tropism tests for HIV and HCV; • surface plasmon resonance assays for measuring receptor-ligand interactions; • multiparameter flow cytometry assays for the phenotypic characterisation of NK or cancer cells; • bioinformatic tools and softwares for sequence and/or pathways analyses, data processing and/or data mining, data management in public health; and • clinically-relevant animal models for the investigation and/or evaluation of new therapies.
MAIN CUSTOMERS/COLLABORATIONS To face the challenges associated with translational research in biomedicine, LIH has developed strong collaborations with local and international leading institutions. The main Luxembourg-based partners that contribute to our impact at a local level are the Centre Hospitalier de Luxembourg, the Integrated Biobank of Luxembourg, the University of Luxembourg and the Luxembourg Center for Systems Biomedicine.
LUXEMBOURG BIOHEALTH CAPABILITIES
71
P R I VAT E S E C TO R PUBLIC RESEARCH
CORE BUSINESS DIRECTOR OF THE ITIS DEPARTMENT Prof. Dr Eric Dubois EMPLOYEES 100-249
ADDRESS 5, avenue des Hauts Fourneaux L-4362 Esch-sur-Alzette CONTACT Prof. Dr Eric Dubois Tel: +352 27 58 88 1 eric.dubois@list.lu WEBSITE www.list.lu/itis
The Luxembourg Institute of Science and Technology (LIST) is a mission-driven Research and Technology Organisation (RTO) that develops advanced technologies and delivers innovative products and services to industry and society. As a major engine of the diversification and growth of Luxembourg’s economy through innovation, LIST supports the deployment of a number of solutions to a wide range of sectors, including energy, IT, telecommunications, environment, agriculture and advanced manufacturing at national and European level. Thanks to its location in an exceptional collaborative environment, namely the Belval Innovation Campus, LIST accelerates time to market by maximising synergies with different actors, including the University of Luxembourg, the national funding agency and industrial clusters. ITIS (IT for Innovative Services), one of the three departments of LIST, focuses on smart systems. In complex, and continuously changing, technical, social and regulatory environments, innovative organisations need smart systems to rapidly analyse, predict and manage the needed transformation and adaptation of their operation. IT is instrumental in the creation of pervasive smartness to provide the needed rapid insights, while integrating business expertise and organisational knowledge for trusted and informed decision making and execution. Committed to multidisciplinary, ITIS conducts research to develop models, methods, software and devices for smart systems, fusing human and technological aspects. ITIS applies also its expertise in the healthcare sector and more specifically advanced ICT applied to healthcare (eHealth) in domain such as: • patient related applications; • standardisation, technical and semantical interoperability; • model-based information engineering and data analysis; • data protection and data privacy; • data security and risk management; • medical imaging and DICOM Tools; and • medical radiation and dose management.
PRODUCTS & SERVICES GECAMed Integrated with the national DSP service (Dossier de Soins Partagé) provided by the national eHealth platform (www.esante.lu), GECAMed is an all-in-one medical office management software that simplifies a large proportion of tasks carried out by healthcare professionals by enabling them to easily access numerous documents on their patients, such as prescriptions or medical test results, regardless of whether they or another doctor recorded them. First launched in 2005 with the support of the Ministry of Health and other sponsors, the software has since been constantly adapted and improved in order to meet the needs of professionals in the healthcare sector in Luxemburg. The software is free and open source, complying with data security and protection guidelines established by the eSanté Agency, and is the first Luxembourgish software that has been certified by IHE Europe, for supporting some of IHE’s high interoperability standards for healthcare systems. Website: www.gecamed.lu
72
LUXEMBOURG BIOHEALTH CAPABILITIES
Luxembourg Institute of Science and Technology (LIST) IT for Innovative Services (ITIS) department
WikiFood WikiFood.eu features an award-winning* online database of the ingredient lists of more than 28,000 food products available in Europe. Uploaded by individual users or provided by food manufacturers, each product listing includes information on the producer, country of origin, full ingredient list with photo and optional information including allergens. Nutritional quality is shown using an easy-to-understand traffic light system. Products on WikiFood.eu can be found by browsing through categories, by excluding specific ingredients, such as gluten or eggs, or by specific characteristics such as high fiber or low fat. In addition to the website, the database can be accessed through mobile apps which enable efficient data entry of ingredient list with OCR text recognition and a natural language processing system. New entries are automatically categorized to identify allergens, synonyms or spelling mistakes.
interoperability of online health, business, procurement and justice functionalities through the re-use of cross-domain IT “building blocks”. The eHealth domain of e-SENS is one of many piloting areas to be tested in the real life environment. LIST collaborates with the Agence eSanté and National Contact Point of Italy, Greece and Portugal to pursue the enhancement of the cross border services started in the former large scale pilot epSOS. The aim is to provide access to patient summaries for citizens and electronic prescriptions for health professionals across Europe. These two “use cases” support the implementation of the Directive 2011/24 on the application of patients’ rights in cross-border healthcare. The Directive obliges also Member States to set up a NCP for cross-border healthcare.
Website: www.wikifood.eu
MAIN CUSTOMERS / COLLABORATIONS
* WikiFood.eu received the “Patient Experience” award at the Luxembourg Healthcare Summit 2015.
National: Agence eSanté; AMMD (Association des Médecins et Médecins Dentistes); Caisse National de Santé; SMA (Service Moyens Accessoires); Croix Rouge; Direction de la Santé; Ministry of Health; Ministry of Social Security; INCCI; LUXITH; Luxembourg hospitals and medical centres; Laboratoires Réunis; Laboratoires Ketterthill; Forges du Sud; Doctena; The Markets Trust; Luxembourg Institute of Health (LIH); University of Luxembourg.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS Model based risk management for a better data security The HEEL (HEalth modELling) project supports the management of cyber risks in the healthcare sector. The project focuses on a participative approach to design reference models of laboratory, radiology and emergency and to share knowledge between all stakeholders in a SaaS risk management tool called MONARC (provided by the GIE Smile). HEEL generates not only value for individual organisations with significant time and effort savings in efficient cyber risk management, but also for the whole healthcare by fostering the implementation of best practices in Luxembourg.
International: EHTEL (European Health Telematics Association)(BE); INRA (FR); Max Planck Institut Informatik (DE); Fachhochschule Trier (DE).
Large scale integration of heterogeneous Medical Data on Chronic Diseases According to the World Health Organization (WHO), the number of patients with chronic disease keeps growing. Early and systematic interventions are highly recommended to prevent health complications and reduce the disease spread. Advances in healthcare such as medical sensors and wearable devices offer new opportunities to accelerate decision making by detecting and predicting unexpected situations. However, the proliferation of such technologies creates new challenges related to data management: data heterogeneity, reliability, and security. The diversity and variety of healthcare data, their huge volume and distribution hinder data processing and analytics to provide timely decisions. Focusing on medical sensors, our research aims at integrating semantic based methods to address the data heterogeneity challenge in big data environments in order to improve the physicians decision making process. e-SENS The main objective of the European project, e-SENS is to ensure the
LUXEMBOURG BIOHEALTH CAPABILITIES
73
P R I VAT E S E C TO R PUBLIC RESEARCH
CORE BUSINESS DIRECTOR OF THE MRT DEPARTMENT Prof. Dr Jens Kriesel EMPLOYEES 100-249
The Luxembourg Institute of Science and Technology (LIST) is a mission-driven Research and Technology Organisation (RTO) that develops advanced technologies and delivers innovative products and services to industry and society. As a major engine of the diversification and growth of Luxembourg’s economy through innovation, LIST supports the deployment of a number of solutions to a wide range of sectors, including energy, IT, telecommunications, environment, agriculture, and advanced manufacturing at national and European level. Thanks to its location in an exceptional collaborative environment, namely the Belval Innovation Campus, LIST accelerates time to market by maximising synergies with different actors, including the University of Luxembourg, the national funding agency and industrial clusters.
CONTACT Dr Thierry Girot Tel: +352 27 58 88 1 thierry.girot@list.lu
MRT (Materials Research and Innovation), one of the three departments of LIST, translates cutting-edge research on smart materials towards industrial innovation. It focuses on two key enabling technologies: nanotechnologies and advanced materials, and investigates research questions related to transducing materials and actuators, photocatalysis and energy harvesters, transparent electronics and smart nanocomposites, point-of-care and drug delivery, modeling and design of structures and multifunctional composites, bio-based polymers and composites, adhesion and compatibilisation of fibres/matrix, process engineering and advanced manufacturing.
WEBSITE www.list.lu/mrt
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS
ADDRESS 5, avenue des Hauts Fourneaux L-4362 Esch-sur-Alzette
Healthcare R&D at MRT focuses on key enabling technologies to address clinical and industry end-user needs in the biomedical and cosmetic sector through devices, surfaces and formulations that are engineered for superior performance. The projects leverage on techniques and skills to design and engineer properties of materials drawing careful correlations between process, geometry and functional properties of materials and surfaces, to advantage for the desired end-use, viz. diagnostic devices, drug-delivery carriers, cosmetic formulations and implant devices. Current skills include capabilities to interrogate or influence biomolecular events through imaging of biomolecules and biological cells at ultra-high resolutions, detection of biomolecules with ultrahigh sensitivity, fabrication of microdevices with nanoscale optical/electronic transducers, composite materials for implants, devices to support design. Current projects include high-throughput microarrays, plasmonic sensors, nanowire sensors, cosmetic formulations, theranostic vectors, high-resolution spectroscopic imaging, biocompatible composite materials, nanostructured implants, AFM-based sub-cellular probing and anti-bacterial interfaces.
TECHNICAL / TECHNOLOGICAL CAPABILITIES The healthcare R&D at MRT is actively supported by advanced capabilities, both existing and newly acquired in the following directions: • synthesis or fabrication of nanostructures in solutions or on surfaces, down to molecular dimensions, and fine-tuning oftheir critical dimensions at will. Finetunability enables structure-property investigations, which is key to rationally tailored nanostructured biological devices/formulations with high performance; • precise (bio)chemical functionalisation of nanostructure surfaces to engineer biomolecular/cell interactions on surface;
74
LUXEMBOURG BIOHEALTH CAPABILITIES
Luxembourg Institute of Science and Technology (LIST) Materials Research and Technology (MRT) department
• high-throughput fabrication of features or arrays in desired nano-, micro- and millimetre scale to support preparation of in-vitro diagnostic devices and implant interfaces; • synthesis of theranostic nanoparticles engineered to yield high performance in imaging and therapy; • preparation of hybrid inorganic/organic formulations incorporating engineered nanostructures with desired optical/electronic properties for cosmeceutical applications; and • investigating biomolecule and cell interactions with nanostructures through a range of spectroscopic and bioimaging tools.
TECHNICAL MEANS / EQUIPMENT Nanomaterials
• ToF-SIMS, D-SIMS and NanoSIMS; • high-resolution mass spectrometry coupled with various ionization sources; and • XRD with (texture, strain measurement, GID and XRR capabilities, hot stage up to 1100°C). Other equipment • Measurement of contact angle and surface energy; • measurement of adhesion: peeling test; • surface profilometry; • tribometry (up to 1,000°C); and • opto-dielectric laboratory (dielectric, ferroelectric, piezoelectric properties).
Up-to-date, industrial and up-scalable process technologies are used: • metal-organic and rapid thermal chemical vapour deposition processes (with direct-liquid precursors injection and plasmaassistance capabilities); • atomic layer deposition processes for 2D/3D materials and powders; including the use of a “fluidised-bed”; • advanced nano-imprint technologies; • advanced reactive focused-ion-beam for nanodeposition, nanoetching and 3D analysis of large area samples; • advanced colloidal synthesis of nano-objects; • advanced wet-chemical processes for controlled materials preparation; and • novel and proprietary technologies for vapour phase polymer deposition.
MAIN CUSTOMERS/COLLABORATIONS More than 70 partners and customers including AcXys Technologies, AGC Flatglass, Aixtron, Annealsys, ArcelorMittal, Cameca, Carl Zeiss, Ceratizit, Circuit Foil, CNES, Dupont de Nemours, Elth, ESA, FEI, Goodyear, Guardian, HEF, L’Oréal, Rotarex, Saint-Gobain, ThalesAlenia Space and Viessmann. Collaborations with universities and research institutes: Institut Jean Lamour (FR), University of Dallas (US), University of Strasbourg (FR), GIGA (BE), University of Louvain-la-Neuve (BE), CRP santé (LU), University of Mons (BE), Materia Nova (BE), University of Angers (FR), University of Twente (NL), University of Technology of Troyes (FR), University of Bordeaux (FR).
Surface treatment • Plasma reactors at atmospheric pressure (DBD plasma; DBD torch; microwave torch) including roll-to-roll wire treatment; • plasma assisted vacuum deposition technologies: magnetron sputtering, IBAD, HIPIMS, PIII&D, including roll-to-roll wire treatment; and • plasma diagnostics (optical spectrometry; electrical measurements; Mass spectrometry, etc.). Materials analysis • Metallography (chemical etching; optical microscopy); • SPM (AFM, EFM, MFM); • electron microscopies and spectroscopies: FE-SEM with EDS and WDS X-Ray microanalysis, TEM with EDS and EELS nano-analysis, FE-AES, XPS, UPS; • FTIR microscopy; • micro raman and tip-enhanced raman spectroscopy (TERS);
LUXEMBOURG BIOHEALTH CAPABILITIES
75
P R I VAT E S E C TO R PUBLIC RESEARCH
CEO Prof. Iris Behrmann EMPLOYEES 50-99
ADDRESS Campus Limpertsberg 162a, avenue de la Faïencerie L-1511 Luxembourg CONTACT Prof. Iris Behrmann Tel: +352 46 66 44 67 40 iris.behrmann@uni.lu WEBSITE http://bio.uni.lu
CORE BUSINESS Using fundamental molecular medicine and integrative systems biology approaches, the objective of the Life Sciences Research Unit is to gain further insights into the molecular mechanisms underlying inflammation and cancer. A particular focus is the analysis of signalling networks which are disturbed in disease situations, with the aim to identify targets for potential therapeutic intervention. Wet lab research is complemented by computational biology approaches. Moreover, members of the Life Sciences Research Unit coordinate and contribute to the teaching of the University of Luxembourg’s study programmes Bachelor in Life Sciences, Master in Integrated Systems Biology and the Doctoral School in Systems and Molecular Medicine. The Research Unit comprises six laboratories: Neuroinflammation, Calcium Signalling, Signal Transduction, Cytoskeleton and Cell Plasticity, Systems Biology, and Molecular Disease Mechanisms.
PRODUCTS & SERVICES • Mathematical modelling and analysis of biological / complex systems; • screening for small molecules which target the actin cytoskeleton; • cell-based assays for drug screening (read-outs: gene expression, proliferation, apoptosis, migration, subcellular translocation of fluorescent proteins); • testing of newly developed antibodies; • concomitant intracellular calcium and superoxide release measurements by fluorometry; • flow cytometry analyses; • confocal microscopy imagery; • several in vitro models of innate immune reaction; • astrogliosis; • differentiation of rodent neural stem cells; • interaction between cultured cells and their substrate; • scientific consulting; • teaching and training in the fields of biochemistry, molecular biology, and cell biology; • teaching and training in the fields of computational biology, bioinformatics, mathematical modelling.
MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTS FNR projects, e.g.: • Tes, a Cancer-Associated LIM-Domain Protein and Novel Actin Nucleator with a Dual Function in the Cytoplasm and the Nucleus (co-funded by FWO); • Inflammasome Function in Neuroinflammation: a Role for Microglia in Parkinson’s Disease; • Inflammatory microRNAs in Liver Cancer (co-funded by DFG).
76
LUXEMBOURG BIOHEALTH CAPABILITIES
University of Luxembourg Life Sciences Research Unit
Fondation Cancer projects, e.g.: • Colon cancer stem cells and hypoxia; • Spinning Disk Confocal System. IBBL project (collaboration with TGen, Phoenix, Arizona, and the ISB, Seattle): • “Melanomics” UL projects, e.g.: • tandem projects with LCSB: “MetaIL6” and “ImMicroDyn1”; • role of notch signalling in the enteric neural stem cells; • regulation of neutrophil functions during inflammation: role of SNARE fusion proteins; • focus on the early step of atherosclerosis: synergetic effect of S100A8/A9 and IL-17D; • investigation of oncogenic signalling pathways initiated by mutated PDGFR and KIT kinases; • molecular circuits linking L-plastin phosphorylation to breast cancer progression.
• a gel/blot detection facility, an Odyssey far-red fluorescence detection facility, a luminometer; • amaxa electroporator, spectrophotometers, Nanodrop devices;
TECHNICAL / TECHNOLOGICAL CAPABILITIES
• phosphoimager;
State-of-the-art technologies in:
• multiwell-plate reader;
• biochemistry;
• automated liquid sample distribution station;
• molecular biology;
• an Incucyte Kinetic Imaging System;
• cell biology;
• PCs / servers with up-to-date Systems Biology and Bioinformatics software to build and analyse mathematical models of biological processes.
• computational biology; • bioinformatics; • mathematical modelling.
TECHNICAL MEANS / EQUIPMENT • Facilities for cell culture, molecular biology and biochemistry; • hypoxia cell culture station; • quantitative epifluorescence cell imaging system (LEICA microscope, Princeton CDD camera) and data exploration software (Metaview); • FACSCanto II flow cytometer; • Zeiss LSM 510 Meta confocal microscope; • Spinning Disk Confocal System; • quantitative real time PCR machines (BIORAD);
MAIN CUSTOMERS / COLLABORATIONS National: Luxembourg Institute of Health (LIH); Centre Hospitalier de Luxembourg; Laboratoire National de Santé; Luxembourg Institute of Science and Technology (LIST); Axoglia; Wafergen International: Institute for Systems Biology, Seattle (USA); TGen, Phoenix (USA); Technische Universität Dresden (DE); University of Stuttgart (DE); Universitätsklinikum des Saarlandes (DE); University of Kuopio (FI); Ottovon-Guericke-University Magdeburg (DE); University of Strasbourg (FR); University of Paris-Sud (FR); Gent University-VIB (BE); Belarus State University, Minsk (BY); DKFZ Heidelberg (DE); EMBL, Heidelberg (DE); IGBMC, Strasbourg (FR); IGMM, Montpellier (FR); University of Exeter (UK)
• fluorimeter; • Beckman ultra-centrifuge; LUXEMBOURG BIOHEALTH CAPABILITIES
77
More information on the Luxembourg Biohealth Cluster:
www.biohealthcluster.lu Follow us on Twitter (@Luxbiohealth) and LinkedIn
c/o LUXINNOVATION GIE 5, avenue des Hauts Fourneaux L-4362 Esch-sur-Alzette Tel: +352 43 62 63 1 www.luxinnovation.lu
The Luxembourg BioHealth Cluster is managed by
With support from